CA3132388A1 - Compositions and methods for treating huntington's disease - Google Patents
Compositions and methods for treating huntington's disease Download PDFInfo
- Publication number
- CA3132388A1 CA3132388A1 CA3132388A CA3132388A CA3132388A1 CA 3132388 A1 CA3132388 A1 CA 3132388A1 CA 3132388 A CA3132388 A CA 3132388A CA 3132388 A CA3132388 A CA 3132388A CA 3132388 A1 CA3132388 A1 CA 3132388A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- adaptor oligonucleotide
- adaptor
- oligonucleotide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 208000023105 Huntington disease Diseases 0.000 title claims abstract description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 76
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 108020004999 messenger RNA Proteins 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 238000000137 annealing Methods 0.000 claims description 51
- 230000008685 targeting Effects 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 30
- 239000012636 effector Substances 0.000 claims description 24
- 108020004688 Small Nuclear RNA Proteins 0.000 claims description 15
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 15
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 claims description 14
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 230000000149 penetrating effect Effects 0.000 claims description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 8
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 31
- 230000030279 gene silencing Effects 0.000 description 30
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000000185 intracerebroventricular administration Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 210000004129 prosencephalon Anatomy 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 108091023037 Aptamer Proteins 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 13
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 101150023903 EIF4A3 gene Proteins 0.000 description 10
- 238000000636 Northern blotting Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 101150043003 Htt gene Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000010412 perfusion Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 101001030705 Homo sapiens Huntingtin Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000005154 hemibrain Anatomy 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100022461 Eukaryotic initiation factor 4A-III Human genes 0.000 description 5
- 101001044466 Homo sapiens Eukaryotic initiation factor 4A-III Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000054185 human HTT Human genes 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001743 silencing effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 4
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000412 dendrimer Substances 0.000 description 4
- 229920000736 dendritic polymer Polymers 0.000 description 4
- -1 morpholino nucleic acids Chemical class 0.000 description 4
- 210000001577 neostriatum Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000015585 poly-pyrimidine tract binding protein Human genes 0.000 description 4
- 108010063723 poly-pyrimidine tract binding protein Proteins 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000001159 caudate nucleus Anatomy 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101100411708 Danio rerio rarga gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108091093094 Glycol nucleic acid Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001233242 Lontra Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 101100338539 Mus musculus Htt gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000018165 U1 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 108010091281 U1 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical group OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229950005031 deutetrabenazine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000004725 selective neuronal vulnerability Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions and methods are provided for the inhibition, treatment and/or prevention of Huntington's disease.
Description
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S
DISEASE
This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 62/815,647, filed March 8, 2019. The foregoing application is incorporated by reference herein.
FIELD OF THE INVENTION
This invention relates generally to the field of gene silencing. Specifically, the invention provides compositions and methods for regulating the expression of the huntingtin gene.
BACKGROUND OF THE INVENTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease. HD is part of the family of polyglutamine (polyQ) disorders comprising at least nine different neurodegenerative diseases that result from the variably expanded trinucleotide CAG repeat in specific genes (e.g., huntingtin) (Walker, F.O.
(2007) Lancet, 369:218-228; Walker, F.O. (2007) Semin. Neurol., 27:143-150). The size of
DISEASE
This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 62/815,647, filed March 8, 2019. The foregoing application is incorporated by reference herein.
FIELD OF THE INVENTION
This invention relates generally to the field of gene silencing. Specifically, the invention provides compositions and methods for regulating the expression of the huntingtin gene.
BACKGROUND OF THE INVENTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease. HD is part of the family of polyglutamine (polyQ) disorders comprising at least nine different neurodegenerative diseases that result from the variably expanded trinucleotide CAG repeat in specific genes (e.g., huntingtin) (Walker, F.O.
(2007) Lancet, 369:218-228; Walker, F.O. (2007) Semin. Neurol., 27:143-150). The size of
2 0 the expansion is partially negatively correlated with age of onset (e.g., adult-onset vs.
juvenile). HD is caused by CAG repeat expansion (¨>36 repeats) within the first exon of the huntingtin gene.
The huntingtin gene (htt) and protein (HTT) are widely and ubiquitously expressed, but the disease has a pattern of selective neuronal vulnerability (e.g., within the brain) (Ambrose, et al. (1994) Somat. Cell Mol. Genet., 20:27-38;
Landles, et al. (2004) EMBO Rep., 5:958-963). Neither the normal function for htt nor the pathological mechanism for mutant htt is completely understood. Multiple mechanisms including a toxic gain of function and loss of wild type function may exist. Notably, aggregates of the HTT protein can be found in different locations and different types of neurons.
There is no cure for HD and treatments are focused on managing its symptoms (Johnson, et al. (2010) Hum. Mol. Genet., 19:R98-R102). Recent data indicate that full length and truncated mRNA transcripts and their associated protein products exist in HD patients and contribute to the mechanism of neuron dysfunction and death (Sathasivam, et al. (2013) Proc. Natl. Acad. Sci., 110:2366-2370). Notably, the use of genetically modified mouse models showed that HD-like disease phenotypes can be resolved if mutant huntingtin expression is eliminated, even at advanced disease stages (Yamamoto, etal. (2000) Cell, 101:57-66; Diaz-Hernandez, etal. (2005) J.
Neurosci., 25:9773-9781). Thus, reducing mutant htt mRNA (full-length and/or terminated) can lead to therapeutic intervention (Sah, et al. (2011) J. Clin.
Invest., 121:500-507). However, improved methods of regulating htt gene expression are required.
SUMMARY OF THE INVENTION
In accordance with the instant invention, nucleic acid molecules for inhibiting the expression of the huntingtin gene (htt) are provided. In a particular embodiment, the nucleic acid molecules comprise an annealing domain operably linked to at least one effector domain, wherein the annealing domain hybridizes to the pre-mRNA
of htt and wherein the effector domain hybridizes to the Ul snRNA of Ul snRNP. In a particular embodiment, the U1 AO may be directed to full-length and/or truncated htt.
In accordance with another aspect of the instant invention, the nucleic acid molecules may be conjugated to (e.g., directly or via a linker) a targeting moiety. The targeting moiety may be conjugated to the 5' end and/or the 3' end (e.g., the nucleic 2 0 acid may comprise two targeting moieties, either the same or different). In a particular embodiment, the nucleic acid molecules are conjugated to an aptamer.
In accordance with another aspect of the invention, methods are provided for inhibiting the expression of htt comprising delivering to a cell at least one of the nucleic acid molecules of the instant invention.
In accordance with another aspect of the invention, compositions are provided which comprise at least one of the nucleic acid molecules of the invention and at least one pharmaceutically acceptable carrier.
In still another aspect, vectors encoding the nucleic acid molecules of the instant invention are also provided.
In accordance with another aspect of the instant invention, methods of treating, inhibiting, and/or preventing Huntington's disease in a subject are provided.
The methods comprise administering a therapeutically effective amount of at least one nucleic acid molecule of the instant invention (e.g., U1A0 or vector encoding the U1 AO) to a subject in need thereof. In a particular embodiment, the method comprises administering more than one U1 AO. In a particular embodiment, the method comprises administering a U1 AO directed to full-length htt, truncated htt, or both full-length and truncated htt (e.g., with separate U1A0).
BRIEF DESCRIPTIONS OF THE DRAWING
Figure 1A is a schematic of a Ul adaptor oligonucleotide depicting its 2 domains: an annealing domain to base pair to the target gene's pre-mRNA in the
juvenile). HD is caused by CAG repeat expansion (¨>36 repeats) within the first exon of the huntingtin gene.
The huntingtin gene (htt) and protein (HTT) are widely and ubiquitously expressed, but the disease has a pattern of selective neuronal vulnerability (e.g., within the brain) (Ambrose, et al. (1994) Somat. Cell Mol. Genet., 20:27-38;
Landles, et al. (2004) EMBO Rep., 5:958-963). Neither the normal function for htt nor the pathological mechanism for mutant htt is completely understood. Multiple mechanisms including a toxic gain of function and loss of wild type function may exist. Notably, aggregates of the HTT protein can be found in different locations and different types of neurons.
There is no cure for HD and treatments are focused on managing its symptoms (Johnson, et al. (2010) Hum. Mol. Genet., 19:R98-R102). Recent data indicate that full length and truncated mRNA transcripts and their associated protein products exist in HD patients and contribute to the mechanism of neuron dysfunction and death (Sathasivam, et al. (2013) Proc. Natl. Acad. Sci., 110:2366-2370). Notably, the use of genetically modified mouse models showed that HD-like disease phenotypes can be resolved if mutant huntingtin expression is eliminated, even at advanced disease stages (Yamamoto, etal. (2000) Cell, 101:57-66; Diaz-Hernandez, etal. (2005) J.
Neurosci., 25:9773-9781). Thus, reducing mutant htt mRNA (full-length and/or terminated) can lead to therapeutic intervention (Sah, et al. (2011) J. Clin.
Invest., 121:500-507). However, improved methods of regulating htt gene expression are required.
SUMMARY OF THE INVENTION
In accordance with the instant invention, nucleic acid molecules for inhibiting the expression of the huntingtin gene (htt) are provided. In a particular embodiment, the nucleic acid molecules comprise an annealing domain operably linked to at least one effector domain, wherein the annealing domain hybridizes to the pre-mRNA
of htt and wherein the effector domain hybridizes to the Ul snRNA of Ul snRNP. In a particular embodiment, the U1 AO may be directed to full-length and/or truncated htt.
In accordance with another aspect of the instant invention, the nucleic acid molecules may be conjugated to (e.g., directly or via a linker) a targeting moiety. The targeting moiety may be conjugated to the 5' end and/or the 3' end (e.g., the nucleic 2 0 acid may comprise two targeting moieties, either the same or different). In a particular embodiment, the nucleic acid molecules are conjugated to an aptamer.
In accordance with another aspect of the invention, methods are provided for inhibiting the expression of htt comprising delivering to a cell at least one of the nucleic acid molecules of the instant invention.
In accordance with another aspect of the invention, compositions are provided which comprise at least one of the nucleic acid molecules of the invention and at least one pharmaceutically acceptable carrier.
In still another aspect, vectors encoding the nucleic acid molecules of the instant invention are also provided.
In accordance with another aspect of the instant invention, methods of treating, inhibiting, and/or preventing Huntington's disease in a subject are provided.
The methods comprise administering a therapeutically effective amount of at least one nucleic acid molecule of the instant invention (e.g., U1A0 or vector encoding the U1 AO) to a subject in need thereof. In a particular embodiment, the method comprises administering more than one U1 AO. In a particular embodiment, the method comprises administering a U1 AO directed to full-length htt, truncated htt, or both full-length and truncated htt (e.g., with separate U1A0).
BRIEF DESCRIPTIONS OF THE DRAWING
Figure 1A is a schematic of a Ul adaptor oligonucleotide depicting its 2 domains: an annealing domain to base pair to the target gene's pre-mRNA in the
3' terminal exon and an effector domain that inhibits maturation of the pre-mRNA
via binding of endogenous Ul snRNP. The provided sequence of the effector domain is SEQ ID NO: 1. Figure 1B is a schematic of the Ul adaptor annealing to target pre-mRNA. The provided sequence of the effector domain is SEQ ID NO: 1. Figure 1C
is a schematic of the Ul adaptor binding Ul snRNP, which leads to poly(A) site inhibition. 1P = pseudouridines of the Ul snRNA in the Ul snRNP. The provided sequence of the Ul snRNA in the Ul snRNP is SEQ ID NO: 2. The provided sequence of the effector domain is SEQ ID NO: 1.
Figure 2 provides a graph showing the percent change of human huntingtin (HTT) mRNA normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) in HD9197 cells transfected for 44 hours with a panel of 20 nM Ul adaptor oligonucleotides (U1A0s) and 20 nM siRNAs directed against full length human HTT.
Figure 3 provides a Western blot of DU145 cells transfected 48 hours with 20 nM various hHTT-FL U1A0s and siRNAs, with the exception of 7 nM in lane 9 and nM in lane 7. GAPDH is provided as a loading control. Ul A (U1 snRNP subunit) is provided as a second loading control. 1,500,00 cell equivalents were loaded per 25 lane. Lanes 4 and 6 are independent replicates. MW: molecular weight markers.
Figure 4A provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after intracerebroventricular (ICV) injection into the left ventricle of saline or hHTT-FL-2 U1A0. YAC128 are a well established mouse model of Huntington's diseases containing the ¨300,000 basepair human huntingtin gene with 30 128 CAG repeats. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 4B provides a graph of the percent change of hHTT-TR mRNA in YAC128 forebrain after ICV injection of saline or hHTT-FL-2 U1 AO. Average of control mice was set to 100%.
Figure 5 provides an image of an 8% denaturing polyacrylamide gel electrophoresis (PAGE) Northern blot of total RNA from YAC128 forebrain after injection of saline or hHTT-FL-2 U1 AO. The probe was a 33 nucleotide 32P-anti-hHTT-FL-2 oligonucleotide. Standards are uninjected U1A0.
Figure 6 provides images of RNAScopeg detection of hHTT-FL in the striatum of saline ICV-treated mice (left) or hTT-FL-2 U1A0 ICV-treated mice (right). Mice were analyzed after a 4 day duration. 4' ,6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei.
Figure 7A provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after ICV-injection of saline or hHTT-FL-2 U1 AO over the indicated times. Average of control mice was set to 100%. Figure 7B provides an image of a Northern blot of total RNA from YAC128 forebrain at the indicated times after injection of saline or hHTT-FL-2 U1A0. The probe was a 33 nucleotide 32P-anti-hHTT-FL-2 oligonucleotide. Standards are uninjected U1A0. Control saline mice 1-7 and mice 11-12 and 16-17 are the same mice as shown in Figures 4 and 5.
Figure 8A provides a graph of the percent change of hHTT-TR mRNA in YAC128 forebrain after ICV-injection of saline, hHTT-TR-1 U1A0, or hHTT-TR-2 U1 AO. Mice tissues were analyzed after a 5 day duration. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 8B provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after injection of saline, hHTT-TR-1 U1A0, or hHTT-TR-2 U1A0. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 9A provides a graph of the percent change of mHTT-TR mRNA in 8-9 month old Q175 forebrain after injection of saline, mHTT-TR-A U1A0, or NC-A
control U1A0. Q175 are a well-established knock-in mouse with ¨175 CAG repeats in the mouse htt gene. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 9B provides a graph of the percent change of mHTT-FL mRNA using the same samples as in Fig. 9A. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
via binding of endogenous Ul snRNP. The provided sequence of the effector domain is SEQ ID NO: 1. Figure 1B is a schematic of the Ul adaptor annealing to target pre-mRNA. The provided sequence of the effector domain is SEQ ID NO: 1. Figure 1C
is a schematic of the Ul adaptor binding Ul snRNP, which leads to poly(A) site inhibition. 1P = pseudouridines of the Ul snRNA in the Ul snRNP. The provided sequence of the Ul snRNA in the Ul snRNP is SEQ ID NO: 2. The provided sequence of the effector domain is SEQ ID NO: 1.
Figure 2 provides a graph showing the percent change of human huntingtin (HTT) mRNA normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) in HD9197 cells transfected for 44 hours with a panel of 20 nM Ul adaptor oligonucleotides (U1A0s) and 20 nM siRNAs directed against full length human HTT.
Figure 3 provides a Western blot of DU145 cells transfected 48 hours with 20 nM various hHTT-FL U1A0s and siRNAs, with the exception of 7 nM in lane 9 and nM in lane 7. GAPDH is provided as a loading control. Ul A (U1 snRNP subunit) is provided as a second loading control. 1,500,00 cell equivalents were loaded per 25 lane. Lanes 4 and 6 are independent replicates. MW: molecular weight markers.
Figure 4A provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after intracerebroventricular (ICV) injection into the left ventricle of saline or hHTT-FL-2 U1A0. YAC128 are a well established mouse model of Huntington's diseases containing the ¨300,000 basepair human huntingtin gene with 30 128 CAG repeats. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 4B provides a graph of the percent change of hHTT-TR mRNA in YAC128 forebrain after ICV injection of saline or hHTT-FL-2 U1 AO. Average of control mice was set to 100%.
Figure 5 provides an image of an 8% denaturing polyacrylamide gel electrophoresis (PAGE) Northern blot of total RNA from YAC128 forebrain after injection of saline or hHTT-FL-2 U1 AO. The probe was a 33 nucleotide 32P-anti-hHTT-FL-2 oligonucleotide. Standards are uninjected U1A0.
Figure 6 provides images of RNAScopeg detection of hHTT-FL in the striatum of saline ICV-treated mice (left) or hTT-FL-2 U1A0 ICV-treated mice (right). Mice were analyzed after a 4 day duration. 4' ,6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei.
Figure 7A provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after ICV-injection of saline or hHTT-FL-2 U1 AO over the indicated times. Average of control mice was set to 100%. Figure 7B provides an image of a Northern blot of total RNA from YAC128 forebrain at the indicated times after injection of saline or hHTT-FL-2 U1A0. The probe was a 33 nucleotide 32P-anti-hHTT-FL-2 oligonucleotide. Standards are uninjected U1A0. Control saline mice 1-7 and mice 11-12 and 16-17 are the same mice as shown in Figures 4 and 5.
Figure 8A provides a graph of the percent change of hHTT-TR mRNA in YAC128 forebrain after ICV-injection of saline, hHTT-TR-1 U1A0, or hHTT-TR-2 U1 AO. Mice tissues were analyzed after a 5 day duration. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 8B provides a graph of the percent change of hHTT-FL mRNA in YAC128 forebrain after injection of saline, hHTT-TR-1 U1A0, or hHTT-TR-2 U1A0. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 9A provides a graph of the percent change of mHTT-TR mRNA in 8-9 month old Q175 forebrain after injection of saline, mHTT-TR-A U1A0, or NC-A
control U1A0. Q175 are a well-established knock-in mouse with ¨175 CAG repeats in the mouse htt gene. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 9B provides a graph of the percent change of mHTT-FL mRNA using the same samples as in Fig. 9A. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
4 Figure 10 provides images of RNAScopeg detection of mHTT-TR in the striatum of saline treated mice (left) or mHTT-TR-A U1 AO treated mice (right) with a 4 day duration.
Figure 11A provides a graph of the percent change of mHTT-TR mRNA in 8-9 month old Q175 mice forebrain twenty-one days after ICV-injection of saline or mHTT-TR-A U1A0. Average of control mice was set to 100%. Figure 11B provides a graph of the percent change of mHTT-FL mRNA in 8-9 month old Q175 mice forebrain twenty-one days after injection of saline or mHTT-TR-A U1 AO.
Average of control mice was set to 100%.
Figure 12A provides a graph of the percent change of mHTT-FL mRNA in 8-9 month old Q175 forebrain after injection of saline, mHTT-FL-A U1A0, or NC-A
control U1A0. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 12B provides a graph of the percent change of mHTT-TR mRNA in Q175 forebrain after injection of saline, mHTT-FL-A
U1 AO, or NC-A control U1 AO. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 13 provides images of RNAScopeg detection of mHTT-FL in the striatum of saline treated mice (left) or mHTT-FL-A U1 AO treated mice (right).
Figures 14A-14L provides target sites in human htt for U1A0 and examples of U1A0 sequences in DNA format. The target sequences in rows 50, 272, 151, 3, 187, 4, 5, 10, and 2 are SEQ ID NOs: 26-34, respectively. The target sequences in rows 1, 6-9, 11-49, 51-150, 152-186, 188-271, and 273-325 are SEQ ID NOs: 40-355, respectively. The U1 AO sequences provided in DNA format are SEQ ID Nos: 356-680, from top to bottom.
Figures 15A-15C provide graphs of the level of silencing of mHTT-F1 and mHTT-Tr at 1 month (Fig. 15A), 2 months (Fig. 15B), and 4 months (Fig. 15C) after ICV injection of mHTT-FL-a U1A0 at four different concentration into Q175 mice.
Figure 15D provides graphs of the level of silencing of mHTT-F1 and mHTT-Tr at month, 2 months, and 4 months after ICV injection of control NC-a U1 AO at 80 tg into Q175 mice.
Figures 16A-16C provide graphs of the level of silencing of mHTT-F1 and mHTT-Tr at 1 month (Fig. 16A), 2 months (Fig. 16B), and 4 months (Fig. 16C) after ICV injection of mHTT-Tr-a U1 AO at four different concentration into Q175 mice.
Figure 11A provides a graph of the percent change of mHTT-TR mRNA in 8-9 month old Q175 mice forebrain twenty-one days after ICV-injection of saline or mHTT-TR-A U1A0. Average of control mice was set to 100%. Figure 11B provides a graph of the percent change of mHTT-FL mRNA in 8-9 month old Q175 mice forebrain twenty-one days after injection of saline or mHTT-TR-A U1 AO.
Average of control mice was set to 100%.
Figure 12A provides a graph of the percent change of mHTT-FL mRNA in 8-9 month old Q175 forebrain after injection of saline, mHTT-FL-A U1A0, or NC-A
control U1A0. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4). Figure 12B provides a graph of the percent change of mHTT-TR mRNA in Q175 forebrain after injection of saline, mHTT-FL-A
U1 AO, or NC-A control U1 AO. Average of control mice was set to 100%. N = 7 are from two different experiments (n = 3 and n = 4).
Figure 13 provides images of RNAScopeg detection of mHTT-FL in the striatum of saline treated mice (left) or mHTT-FL-A U1 AO treated mice (right).
Figures 14A-14L provides target sites in human htt for U1A0 and examples of U1A0 sequences in DNA format. The target sequences in rows 50, 272, 151, 3, 187, 4, 5, 10, and 2 are SEQ ID NOs: 26-34, respectively. The target sequences in rows 1, 6-9, 11-49, 51-150, 152-186, 188-271, and 273-325 are SEQ ID NOs: 40-355, respectively. The U1 AO sequences provided in DNA format are SEQ ID Nos: 356-680, from top to bottom.
Figures 15A-15C provide graphs of the level of silencing of mHTT-F1 and mHTT-Tr at 1 month (Fig. 15A), 2 months (Fig. 15B), and 4 months (Fig. 15C) after ICV injection of mHTT-FL-a U1A0 at four different concentration into Q175 mice.
Figure 15D provides graphs of the level of silencing of mHTT-F1 and mHTT-Tr at month, 2 months, and 4 months after ICV injection of control NC-a U1 AO at 80 tg into Q175 mice.
Figures 16A-16C provide graphs of the level of silencing of mHTT-F1 and mHTT-Tr at 1 month (Fig. 16A), 2 months (Fig. 16B), and 4 months (Fig. 16C) after ICV injection of mHTT-Tr-a U1 AO at four different concentration into Q175 mice.
5 Figure 17 provide graphs of the pharmacokinetics of mHTT-FL-a U1A0 (top), mHTT-Tr-a U1A0 (middle), and NC-a U1A0 (bottom). The amount of RNA
is shown at 1 month, 2 months, and 4 months. Each of the four different concentration of mHTT-FL-a U1 AO and mHTT-Tr-a U1 AO are shown while only the 80 i.tg concentration for NC-a U1A0 is shown.
DETAILED DESCRIPTION OF THE INVENTION
Ul Adaptors (or Ul adaptor oligonucleotides (U1A0)) are an oligonucleotide-mediated gene silencing technology which are mechanistically distinct from antisense or siRNA. Ul Adaptors act by selectively interfering with a key step in mRNA
maturation: the addition of a 3' polyadenosine (polyA) tail. Nearly all protein-coding mRNAs require a polyA tail and the failure to add one results in rapid degradation of the nascent mRNA inside the nucleus, thereby preventing expression of a protein product. Ul Adaptors have been described in U.S. Patent No. 9,441,221; U.S.
Patent No. 9,078,823; U.S. Patent No. 8,907,075; and U.S. Patent No. 8,343,941 (each of which is incorporated by reference herein).
Ul Adaptor oligonucleotides are well suited to in vivo applications because they can accept extensive chemical modifications to improve nuclease resistance and the attachment of bulky groups, such as tags for imaging or ligands for receptor-2 0 mediated uptake by target cells, without loss of silencing activity.
Huntington's disease has several characteristics that make it a particularly well suited for treatment using U1 AO. First, reducing expression of the mutant htt gene will be beneficial in slowing and/or halting neurodegeneration. Second, the disease can be diagnosed with certainty via genetic testing. Third, the disease usually has an adult onset.
Fourth, the disease is slowly progressive and well documented, with a predictable course.
Fifth, both the clinical exam and non-invasive methods are available to follow the progression of disease and determine if interventions are beneficial. Sixth, the caudate nucleus is a region prominently affected, can be monitored with imaging, and lies close to the cerebral ventricle for diffusion from interventions administered in the ventricular system. Lastly, the highly vulnerable medium spiny neurons in the caudate nucleus have been well studied and express markers that can be useful for cell directed targeting by modified carriers.
Provided herein are methods and compositions for the modulation of the expression of htt, particularly mutant htt (htt comprising expanded trinucleotide CAG
is shown at 1 month, 2 months, and 4 months. Each of the four different concentration of mHTT-FL-a U1 AO and mHTT-Tr-a U1 AO are shown while only the 80 i.tg concentration for NC-a U1A0 is shown.
DETAILED DESCRIPTION OF THE INVENTION
Ul Adaptors (or Ul adaptor oligonucleotides (U1A0)) are an oligonucleotide-mediated gene silencing technology which are mechanistically distinct from antisense or siRNA. Ul Adaptors act by selectively interfering with a key step in mRNA
maturation: the addition of a 3' polyadenosine (polyA) tail. Nearly all protein-coding mRNAs require a polyA tail and the failure to add one results in rapid degradation of the nascent mRNA inside the nucleus, thereby preventing expression of a protein product. Ul Adaptors have been described in U.S. Patent No. 9,441,221; U.S.
Patent No. 9,078,823; U.S. Patent No. 8,907,075; and U.S. Patent No. 8,343,941 (each of which is incorporated by reference herein).
Ul Adaptor oligonucleotides are well suited to in vivo applications because they can accept extensive chemical modifications to improve nuclease resistance and the attachment of bulky groups, such as tags for imaging or ligands for receptor-2 0 mediated uptake by target cells, without loss of silencing activity.
Huntington's disease has several characteristics that make it a particularly well suited for treatment using U1 AO. First, reducing expression of the mutant htt gene will be beneficial in slowing and/or halting neurodegeneration. Second, the disease can be diagnosed with certainty via genetic testing. Third, the disease usually has an adult onset.
Fourth, the disease is slowly progressive and well documented, with a predictable course.
Fifth, both the clinical exam and non-invasive methods are available to follow the progression of disease and determine if interventions are beneficial. Sixth, the caudate nucleus is a region prominently affected, can be monitored with imaging, and lies close to the cerebral ventricle for diffusion from interventions administered in the ventricular system. Lastly, the highly vulnerable medium spiny neurons in the caudate nucleus have been well studied and express markers that can be useful for cell directed targeting by modified carriers.
Provided herein are methods and compositions for the modulation of the expression of htt, particularly mutant htt (htt comprising expanded trinucleotide CAG
6 repeats, including full-length and/or truncated). The methods comprise the use of a Ul adaptor oligonucleotide/ molecule (see, generally, Figure 1). In its simplest form, the U1A0 is an oligonucleotide with two domains: (1) an annealing domain designed to base pair to the htt gene's pre-mRNA (e.g., in the terminal exon) and (2) an effector domain (also referred to as the Ul domain) that inhibits 3'-end formation of the target pre-mRNA via binding endogenous Ul snRNP. Without being bound by theory, the Ul adaptor tethers endogenous Ul snRNP to a gene-specific pre-mRNA and the resulting complex blocks proper 3' end formation. Notably, Ul snRNP is highly abundant (-1 million/mammalian cell nucleus) and in stoichiometric excess compared to other spliceosome components. Therefore, there are no deleterious effects of titrating out endogenous Ul snRNP.
The U1A0 is able to enter cells either alone or in complex with delivery reagents (e.g., lipid-based transfection reagents). The U1A0 should also be capable of entering the nucleus to bind to pre-mRNA. Indeed, this property has already been established for small nucleic acid molecules such as in those antisense approaches that utilize the RNase H pathway where the oligo enters the nucleus and binds to pre-mRNA. Additionally, it has been showed that antisense oligos can bind to nuclear pre-mRNA and sterically block access of splicing factors leading to altered splicing patterns (Ittig et al. (2004) Nuc. Acids Res., 32:346-53).
In a particular embodiment, the annealing domain of the Ul adaptor molecule is designed to have high affinity and specificity to the target site on the target pre-mRNA (e.g., to the exclusion of other pre-mRNAs). In a particular embodiment, a balance should be achieved between having the annealing domain too short, as this will jeopardize affinity, or too long, as this will promote "off-target"
effects or alter other cellular pathways. Furthermore, the annealing domain should not interfere with the function of the effector domain (for example, by base pairing and hairpin formation). The U1 AO annealing domain does not have an absolute requirement on length. However, the annealing domain will typically be from about 10 to about nucleotides in length, more typically from about 10 to about 30 nucleotides or about 10 to about 20 nucleotides. In a particular embodiment, the annealing domain is at least about 13 or 15 nucleotides in length. The annealing domain may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or, more particularly, 100% complementary to the gene of interest (htt). In one embodiment, the annealing domain hybridizes with a target site within the 3' terminal exon, which
The U1A0 is able to enter cells either alone or in complex with delivery reagents (e.g., lipid-based transfection reagents). The U1A0 should also be capable of entering the nucleus to bind to pre-mRNA. Indeed, this property has already been established for small nucleic acid molecules such as in those antisense approaches that utilize the RNase H pathway where the oligo enters the nucleus and binds to pre-mRNA. Additionally, it has been showed that antisense oligos can bind to nuclear pre-mRNA and sterically block access of splicing factors leading to altered splicing patterns (Ittig et al. (2004) Nuc. Acids Res., 32:346-53).
In a particular embodiment, the annealing domain of the Ul adaptor molecule is designed to have high affinity and specificity to the target site on the target pre-mRNA (e.g., to the exclusion of other pre-mRNAs). In a particular embodiment, a balance should be achieved between having the annealing domain too short, as this will jeopardize affinity, or too long, as this will promote "off-target"
effects or alter other cellular pathways. Furthermore, the annealing domain should not interfere with the function of the effector domain (for example, by base pairing and hairpin formation). The U1 AO annealing domain does not have an absolute requirement on length. However, the annealing domain will typically be from about 10 to about nucleotides in length, more typically from about 10 to about 30 nucleotides or about 10 to about 20 nucleotides. In a particular embodiment, the annealing domain is at least about 13 or 15 nucleotides in length. The annealing domain may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or, more particularly, 100% complementary to the gene of interest (htt). In one embodiment, the annealing domain hybridizes with a target site within the 3' terminal exon, which
7 includes the terminal coding region and the 3'UTR and polyadenylation signal sequences (e.g., through the polyadenylation site). In another embodiment, the target sequence is within about 500 basepair, about 250 basepair, about 100 basepair, or about 50 bp of the poly(A) signal sequence.
The CAG (encoding glutamine) disease expansion (typically greater than 36 repeats) in HTT is located within the 1st exon of the HTT gene (The Huntington's Disease Collaborative Research Group (1993) Cell 72:971-983). A short exon 1 HTT
polyadenylated mRNA resulting from aberrant splicing of the mutant allele is translated into a pathogenic exon 1 HTT protein that contributes to disease progression (Sathasivam et al. (2013) Proc. Natl. Acad. Sci., 110:2366-2370;
Gipson et al. (2013) RNA Biol., 10:1647-1652). Exemplary amino acid and nucleotide sequences of human HTT and htt can be found, for example, in Gene ID: 3064 and GenBank Accession Nos. NM 002111.8 and NP 002102.4.
Target sites within htt for the U1 AO have been identified herein using selection criteria for gene silencing. Figures 14A-14L list target sites within htt for the U1 AO with the best scoring target sites listed first. In a particular embodiment, the annealing domain hybridizes with a target site provided in Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-278 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-192 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-58 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-26 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-10 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site selected from:
CCCACATGTCATCAGCAGGA (SEQ ID NO: 26);
CAGCAGGATGGGCAAGCTGG (SEQ ID NO: 27);
GAGCAGGTGGACGTGAACCT (SEQ ID NO: 28);
GTGGACGTGAACCTTTTCTG (SEQ ID NO: 29);
TCTGCCTGGTCGCCACAGAC (SEQ ID NO: 30);
GTCTGTGCTTGAGGTGGTTG (SEQ ID NO: 31):
GCTGCTGACTTGTTTACGAA (SEQ ID NO: 32);
GGTGGGAGAGACTGTGAGGC (SEQ ID NO: 33);
The CAG (encoding glutamine) disease expansion (typically greater than 36 repeats) in HTT is located within the 1st exon of the HTT gene (The Huntington's Disease Collaborative Research Group (1993) Cell 72:971-983). A short exon 1 HTT
polyadenylated mRNA resulting from aberrant splicing of the mutant allele is translated into a pathogenic exon 1 HTT protein that contributes to disease progression (Sathasivam et al. (2013) Proc. Natl. Acad. Sci., 110:2366-2370;
Gipson et al. (2013) RNA Biol., 10:1647-1652). Exemplary amino acid and nucleotide sequences of human HTT and htt can be found, for example, in Gene ID: 3064 and GenBank Accession Nos. NM 002111.8 and NP 002102.4.
Target sites within htt for the U1 AO have been identified herein using selection criteria for gene silencing. Figures 14A-14L list target sites within htt for the U1 AO with the best scoring target sites listed first. In a particular embodiment, the annealing domain hybridizes with a target site provided in Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-278 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-192 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-58 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-26 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site provided in rows 1-10 of Figures 14A-14L. In a particular embodiment, the annealing domain hybridizes with a target site selected from:
CCCACATGTCATCAGCAGGA (SEQ ID NO: 26);
CAGCAGGATGGGCAAGCTGG (SEQ ID NO: 27);
GAGCAGGTGGACGTGAACCT (SEQ ID NO: 28);
GTGGACGTGAACCTTTTCTG (SEQ ID NO: 29);
TCTGCCTGGTCGCCACAGAC (SEQ ID NO: 30);
GTCTGTGCTTGAGGTGGTTG (SEQ ID NO: 31):
GCTGCTGACTTGTTTACGAA (SEQ ID NO: 32);
GGTGGGAGAGACTGTGAGGC (SEQ ID NO: 33);
8 TCCTTTCTCCTGATAGTCAC (SEQ ID NO: 34);
GCGGGGATGGCGGTAACCCT (SEQ ID NO: 35); or GTCTTCCCTTGTCCTCTCGC (SEQ ID NO: 36).
In a particular embodiment, the annealing domain hybridizes with GTGGACGTGAACCTTTTCTG (SEQ ID NO: 29). The annealing domain may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or, more particularly, 100% complementary to any target sequence within Figures 14L or any one of SEQ ID NO: 26-36. The annealing domain may comprise additional or fewer nucleotides at the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID NO: 26-36. For example, the annealing domain may comprise at least 1, 2, 3, 4, 5, or up to 10 or 20 nucleotides added to the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID
NO: 26-36 (e.g., from the sequence of the htt gene) or may have a deletion of at least 1, 2, 3, 4, or 5 nucleotides from the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID NO: 26-36.
In a particular embodiment, the Ul domain of the U1A0 binds with high affinity to Ul snRNP. In a particular embodiment, the Ul domain is complementary to nucleotides 2-11 of endogenous Ul snRNA. In a particular embodiment, the Ul domain comprises 5'-CAGGUAAGUA-3' (SEQ ID NO: 1); 5'-CAGGUAAGUAU-2 0 3' (SEQ ID NO: 4); 5'-GCCAGGUAAGUAU-3' (SEQ ID NO: 5). In a particular embodiment, the Ul domain comprises the sequence 5'-CAGGUAAGUA-3' (SEQ
ID NO: 1). In a particular embodiment, the Ul domain comprises the sequence 5'-GCCAGGUAAGUAU-3' (SEQ ID NO: 5). In another embodiment, the Ul domain has at least 70%, at least 75%, at least 80%, at least 85%, and more particularly at least 90%, at least 95%, or at least 97% identity to SEQ ID NO: 1, SEQ ID NO:
4, or SEQ ID NO: 5. The Ul domain may comprise additional nucleotides 5' or 3' to SEQ
ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5. For example, the Ul domain may comprise at least 1, 2, 3, 4, 5, or up to 10 or 20 nucleotides 5' or 3' to SEQ
ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5. Indeed, increasing the length of the Ul domain to include basepairing into stem 1 and/or basepairing to position 1 of Ul snRNA
improves the Ul adaptor's affinity to Ul snRNP. The effector domain may be from about 8 nucleotides to about 30 nucleotides, from about 10 nucleotides to about 20 nucleotides, or from about 10 to about 15 nucleotides in length. For example, the
GCGGGGATGGCGGTAACCCT (SEQ ID NO: 35); or GTCTTCCCTTGTCCTCTCGC (SEQ ID NO: 36).
In a particular embodiment, the annealing domain hybridizes with GTGGACGTGAACCTTTTCTG (SEQ ID NO: 29). The annealing domain may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or, more particularly, 100% complementary to any target sequence within Figures 14L or any one of SEQ ID NO: 26-36. The annealing domain may comprise additional or fewer nucleotides at the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID NO: 26-36. For example, the annealing domain may comprise at least 1, 2, 3, 4, 5, or up to 10 or 20 nucleotides added to the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID
NO: 26-36 (e.g., from the sequence of the htt gene) or may have a deletion of at least 1, 2, 3, 4, or 5 nucleotides from the 5' and/or 3' end of any target sequence within Figures 14A-14L or any one of SEQ ID NO: 26-36.
In a particular embodiment, the Ul domain of the U1A0 binds with high affinity to Ul snRNP. In a particular embodiment, the Ul domain is complementary to nucleotides 2-11 of endogenous Ul snRNA. In a particular embodiment, the Ul domain comprises 5'-CAGGUAAGUA-3' (SEQ ID NO: 1); 5'-CAGGUAAGUAU-2 0 3' (SEQ ID NO: 4); 5'-GCCAGGUAAGUAU-3' (SEQ ID NO: 5). In a particular embodiment, the Ul domain comprises the sequence 5'-CAGGUAAGUA-3' (SEQ
ID NO: 1). In a particular embodiment, the Ul domain comprises the sequence 5'-GCCAGGUAAGUAU-3' (SEQ ID NO: 5). In another embodiment, the Ul domain has at least 70%, at least 75%, at least 80%, at least 85%, and more particularly at least 90%, at least 95%, or at least 97% identity to SEQ ID NO: 1, SEQ ID NO:
4, or SEQ ID NO: 5. The Ul domain may comprise additional nucleotides 5' or 3' to SEQ
ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5. For example, the Ul domain may comprise at least 1, 2, 3, 4, 5, or up to 10 or 20 nucleotides 5' or 3' to SEQ
ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5. Indeed, increasing the length of the Ul domain to include basepairing into stem 1 and/or basepairing to position 1 of Ul snRNA
improves the Ul adaptor's affinity to Ul snRNP. The effector domain may be from about 8 nucleotides to about 30 nucleotides, from about 10 nucleotides to about 20 nucleotides, or from about 10 to about 15 nucleotides in length. For example, the
9 effector domain may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
The insertion of point mutations into the Ul domain, i.e., diverging from the consensus sequence SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5, can moderate silencing. Indeed, altering the consensus sequence will produce Ul domains of different strength and affinity for the Ul snRNA, thereby leading to different levels of silencing. Therefore, once an annealing domain has been determined for a gene of interest, different Ul domains of different strength can be attached to the annealing domain to effect different levels of silencing of the gene of interest. For example, gAGGUAAGUA (SEQ ID NO: 3) would bind more weakly to Ul snRNP than SEQ
ID NO: 1 and, therefore, would produce a lower level of silencing. As discussed above, nucleotide analogues can be included in the Ul domain to increase the affinity to endogenous Ul snRNP. The addition of nucleotide analogs may not be considered a point mutation if the nucleotide analog binds the same nucleotide as the replaced nucleotide.
The U1 AO may be modified to be resistant to nucleases. In a particular embodiment, the U1 AO may comprise at least one non-natural nucleotide and/or nucleotide analog. The nucleotide analogs may be used to increase annealing affinity, specificity, bioavailability in the cell and organism, cellular and/or nuclear transport, 2 0 stability, and/or resistance to degradation. For example, it has been well-established that inclusion of Locked Nucleic Acid (LNA) bases within an oligonucleotide increases the affinity and specificity of annealing of the oligonucleotide to its target site (Kauppinen et al. (2005) Drug Discov. Today Tech., 2:287-290; Orum et al.
(2004) Letters Peptide Sci., 10:325-334). Unlike RNAi and RNase H-based silencing technologies, U1A0 inhibition does not involve enzymatic activity. As such, there is significantly greater flexibility in the permissible nucleotide analogs that can be employed in the U1A0 when compared with oligos for RNAi and RNase H-based silencing technologies.
Nucleotide analogs include, without limitation, nucleotides with phosphate modifications comprising one or more phosphorothioate, phosphorodithioate, phosphodiester, methyl phosphonate, phosphoramidate, methylphosphonate, phosphotriester, phosphoroaridate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl substitutions (see, e.g., Hunziker and Leumann (1995) Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417; Mesmaeker et al. (1994) Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39); nucleotides with modified sugars (see, e.g., U.S. Patent Application Publication No. 2005/0118605) and sugar modifications such as 2'-0-methyl (2'-0-methylnucleotides), 2'-0-methyloxyethoxy, and 2'-halo (e.g., 2'-fluoro); and nucleotide mimetics such as, without limitation, peptide nucleic acids (PNA), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acid, threose nucleic acid, and locked nucleic acids (LNA) (see, e.g., U.S. Patent Application Publication No. 2005/0118605). Other nucleotide modifications are also provided in U.S. Patent Nos. 5,886,165; 6,140,482;
5,693,773;
5,856,462; 5,973,136; 5,929,226; 6,194,598; 6,172,209; 6,175,004; 6,166,197;
6,166,188; 6,160,152; 6,160,109; 6,153,737; 6,147,200; 6,146,829; 6,127,533;
and 6,124,445. In a particular embodiment, the U1 AO comprises at least one locked nucleic acid. In a particular embodiment, the annealing domain comprises at least one locked nucleic acid (optionally where the effector domain does not contain a locked nucleic acid). In a particular embodiment, the U1 AO, particularly the annealing domain, has locked nucleic acids spaced apart by 2-4 nucleotides, particularly three nucleotides.
2 0 Notably, care should be taken so as to not design a Ul adaptor wherein the effector domain has significant affinity for the target site of the mRNA or the sites immediately flanking the target site. In other words, the target site should be selected so as to minimize the base pairing potential of the effector domain with the target pre-mRNA, especially the portion flanking upstream of the annealing site.
To increase the silencing ability of the U1A0, the U1A0 should also be designed to have low self annealing so as to prevent the formation of hairpins within a single Ul adaptor and/or the formation of homodimers or homopolymers between two or more Ul adaptors.
The annealing and effector domains of the U1A0 may be linked such that the effector domain is at the 5' end and/or 3' end of the annealing domain.
Further, the annealing and effector domains may be operably linked via a linker domain. The linker domain may comprise, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15, up to 20, or up to 25 nucleotides.
The U1A0 may comprise ribonucleotides and/or deoxynucleotides. With regard to the sequences provided herein, uracil bases and thymidine bases may be exchanged. In a particular embodiment, the U1A0 comprises 2'-0-methyl nucleotides, 2'-0-methyloxyethoxy nucleotides, 2'-halo (e.g., 2'-fluoro), and/or locked nucleic acids. In a particular embodiment, the U1A0 comprises phosphorothioates.
In a particular embodiment, the U1A0 comprises a U1A0 provided in Figures 14A-14L (particularly in RNA). In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-278 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-192 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1 AO
sequence provided in rows 1-58 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-26 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-
The insertion of point mutations into the Ul domain, i.e., diverging from the consensus sequence SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5, can moderate silencing. Indeed, altering the consensus sequence will produce Ul domains of different strength and affinity for the Ul snRNA, thereby leading to different levels of silencing. Therefore, once an annealing domain has been determined for a gene of interest, different Ul domains of different strength can be attached to the annealing domain to effect different levels of silencing of the gene of interest. For example, gAGGUAAGUA (SEQ ID NO: 3) would bind more weakly to Ul snRNP than SEQ
ID NO: 1 and, therefore, would produce a lower level of silencing. As discussed above, nucleotide analogues can be included in the Ul domain to increase the affinity to endogenous Ul snRNP. The addition of nucleotide analogs may not be considered a point mutation if the nucleotide analog binds the same nucleotide as the replaced nucleotide.
The U1 AO may be modified to be resistant to nucleases. In a particular embodiment, the U1 AO may comprise at least one non-natural nucleotide and/or nucleotide analog. The nucleotide analogs may be used to increase annealing affinity, specificity, bioavailability in the cell and organism, cellular and/or nuclear transport, 2 0 stability, and/or resistance to degradation. For example, it has been well-established that inclusion of Locked Nucleic Acid (LNA) bases within an oligonucleotide increases the affinity and specificity of annealing of the oligonucleotide to its target site (Kauppinen et al. (2005) Drug Discov. Today Tech., 2:287-290; Orum et al.
(2004) Letters Peptide Sci., 10:325-334). Unlike RNAi and RNase H-based silencing technologies, U1A0 inhibition does not involve enzymatic activity. As such, there is significantly greater flexibility in the permissible nucleotide analogs that can be employed in the U1A0 when compared with oligos for RNAi and RNase H-based silencing technologies.
Nucleotide analogs include, without limitation, nucleotides with phosphate modifications comprising one or more phosphorothioate, phosphorodithioate, phosphodiester, methyl phosphonate, phosphoramidate, methylphosphonate, phosphotriester, phosphoroaridate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl substitutions (see, e.g., Hunziker and Leumann (1995) Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417; Mesmaeker et al. (1994) Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39); nucleotides with modified sugars (see, e.g., U.S. Patent Application Publication No. 2005/0118605) and sugar modifications such as 2'-0-methyl (2'-0-methylnucleotides), 2'-0-methyloxyethoxy, and 2'-halo (e.g., 2'-fluoro); and nucleotide mimetics such as, without limitation, peptide nucleic acids (PNA), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acid, threose nucleic acid, and locked nucleic acids (LNA) (see, e.g., U.S. Patent Application Publication No. 2005/0118605). Other nucleotide modifications are also provided in U.S. Patent Nos. 5,886,165; 6,140,482;
5,693,773;
5,856,462; 5,973,136; 5,929,226; 6,194,598; 6,172,209; 6,175,004; 6,166,197;
6,166,188; 6,160,152; 6,160,109; 6,153,737; 6,147,200; 6,146,829; 6,127,533;
and 6,124,445. In a particular embodiment, the U1 AO comprises at least one locked nucleic acid. In a particular embodiment, the annealing domain comprises at least one locked nucleic acid (optionally where the effector domain does not contain a locked nucleic acid). In a particular embodiment, the U1 AO, particularly the annealing domain, has locked nucleic acids spaced apart by 2-4 nucleotides, particularly three nucleotides.
2 0 Notably, care should be taken so as to not design a Ul adaptor wherein the effector domain has significant affinity for the target site of the mRNA or the sites immediately flanking the target site. In other words, the target site should be selected so as to minimize the base pairing potential of the effector domain with the target pre-mRNA, especially the portion flanking upstream of the annealing site.
To increase the silencing ability of the U1A0, the U1A0 should also be designed to have low self annealing so as to prevent the formation of hairpins within a single Ul adaptor and/or the formation of homodimers or homopolymers between two or more Ul adaptors.
The annealing and effector domains of the U1A0 may be linked such that the effector domain is at the 5' end and/or 3' end of the annealing domain.
Further, the annealing and effector domains may be operably linked via a linker domain. The linker domain may comprise, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15, up to 20, or up to 25 nucleotides.
The U1A0 may comprise ribonucleotides and/or deoxynucleotides. With regard to the sequences provided herein, uracil bases and thymidine bases may be exchanged. In a particular embodiment, the U1A0 comprises 2'-0-methyl nucleotides, 2'-0-methyloxyethoxy nucleotides, 2'-halo (e.g., 2'-fluoro), and/or locked nucleic acids. In a particular embodiment, the U1A0 comprises phosphorothioates.
In a particular embodiment, the U1A0 comprises a U1A0 provided in Figures 14A-14L (particularly in RNA). In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-278 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-192 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1 AO
sequence provided in rows 1-58 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-26 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises a U1A0 sequence provided in rows 1-
10 of Figures 14A-14L. In a particular embodiment, the U1A0 comprises:
UCCUGCUGAUGACAUGUGGGGCCAGGUAAGUAU (SEQ ID NO: 8);
CCAGCUUGCCCAUCCUGCUGGCCAGGUAAGUAU (SEQ ID NO: 37);
AGGUUCACGUCCACCUGCUCGCCAGGUAAGUAU (SEQ ID NO: 38);
CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 9);
GUCUGUGGCGACCAGGCAGAGCCAGGUAAGUAU (SEQ ID NO: 39);
CAACCACCUCAAGCACAGACGCCAGGUAAGUAU (SEQ ID NO: 10):
UUCGUAAACAAGUCAGCAGCGCCAGGUAAGUAU (SEQ ID NO: 11);
GCCUCACAGUCUCUCCCACCGCCAGGUAAGUAU (SEQ ID NO: 12);
GUGACUAUCAGGAGAAAGGAGCCAGGUAAGUAU (SEQ ID NO: 13);
CAGAAAAGGTUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 14);
AGGGUTACCGCCATCCCCGCGCCAGGUAAGUAU (SEQ ID NO: 15);
or GCGAGAGGACAAGGGAAGACGCCAGGUAAGUAU (SEQ ID NO: 16).
In a particular embodiment, the U1A0 comprises CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 9). In another embodiment, the U1A0 has at least 70%, at least 75%, at least 80%, at least 85%, and more particularly at least 90%, at least 95%, at least 97% or more identity with one of the above sequences or in Figures 14A-14L. With regard to the sequences provided herein, uracil bases and thymidine bases may be exchanged. In a particular embodiment, the U1A0 comprises at least one or all nucleotide analogs. In a particular embodiment, the U1A0 comprises 2'-0-methyl nucleotides, 2'-0-methyloxyethoxy nucleotides, 2'-halo (e.g., 2'-fluoro), and/or locked nucleic acids.
In a particular embodiment, the U1A0 comprises phosphorothioates. In a particular embodiment, the U1A0 are modified as set forth in the Example.
In another embodiment of the instant invention, more than one U1A0 directed to a gene of interest (htt) may be used to modulate expression. Multiple U1A0 targeting (annealing) to different sequences in the same pre-mRNA can provide enhanced inhibition. Compositions of the instant invention may comprise more than one U1A0 directed to the htt gene (e.g., different targets within the htt gene).
In still another embodiment, the U1A0 can be combined with other methods of modulating the expression of a gene of interest. For example, a U1A0 can be used in coordination with other inhibitory nucleic acid molecules such as antisense oligonucleotides or RNase H-based methods, RNAi, miRNA, and morpholino-based methods to give enhanced inhibition. Inasmuch as U1A0 utilize a different mechanism than these other approaches, the combined use will result in an increased inhibition of gene expression compared to the use of a single inhibitory agent alone.
Indeed, U1A0 may target the biosynthetic step in the nucleus whereas RNAi and certain antisense approaches generally target cytoplasmic stability or translatability of a pre-existing pool of mRNA.
In another aspect of the instant invention, the effector domain of the Ul adaptor can be replaced with the binding site for any one of a number of nuclear factors that regulate gene expression. For example, the binding site for polypyrimidine tract binding protein (PTB) is short and PTB is known to inhibit poly(A) sites. Thus, replacing the effector domain with a high affinity PTB
binding site would also silence expression of the target gene.
There are Ul snRNA genes that vary in sequence from the canonical Ul snRNA described hereinabove. Collectively, these Ul snRNA genes can be called the Ul variant genes. Some Ul variant genes are described in GenBank Accession Nos.
L78810, ACO25268, ACO25264 and AL592207 and in Kyriakopoulou et al. (RNA
(2006) 12:1603-11), which identified close to 200 potential Ul snRNA-like genes in the human genome. Since some of these Ul variants have a 5' end sequence different than canonical Ul snRNA, one plausible function is to recognize alternative splice signals during pre-mRNA splicing. Accordingly, the Ul domain of the U1A0 of the instant invention may be designed to hybridize with the 5' end of the Ul variant snRNA in the same way as the Ul domain was designed to hybridize with the canonical Ul snRNA as described herein. The U1A0 which hybridize to the Ul variants may then be used to modulate the expression of a gene of interest.
There are many advantages of the Ul adaptor technology to other existing silencing technologies. Certain of these advantages are as follows. First, the separates into two independent domains: (1) the annealing (i.e., targeting) activity and (2) the inhibitory activity, thereby allowing one to optimize annealing without affecting the inhibitory activity or vice versa. Second, as compared to other technologies, usage of two U1A0 to target the same gene gives additive even synergistic inhibition. Third, the U1A0 has a novel inhibitory mechanism.
Therefore, it will be compatible when used in combination with other methods.
Fourth, the U1 AO inhibits the biosynthesis of mRNA by inhibiting the critical, nearly-universal, pre-mRNA maturation step of poly(A) tail addition (also called 3' end processing).
Compositions of the instant invention comprise at least one U1 AO of the instant invention and at least one pharmaceutically acceptable carrier. The compositions may further comprise at least one other agent which inhibits the expression of the gene of interest (htt). For example, the composition may further 2 0 comprise at least one siRNA or antisense oligonucleotide directed against the gene of interest (htt).
The U1A0 of the present invention may be administered alone, as naked polynucleotides, to cells or an organism, including animals and humans. The may be administered with an agent which enhances its uptake by cells. In a particular embodiment, the U1A0 may be contained within a liposome, nanoparticle, or polymeric composition.
In another embodiment, the U1A0 may be delivered to a cell or animal, including humans, in an expression vector such as a plasmid or viral vector.
For example, a U1A0 can be expressed from a vector such as a plasmid or a virus.
Expression of such short RNAs from a plasmid or virus has become routine and can be easily adapted to express a U1A0. Expression vectors for the expression of RNA
molecules may employ a strong promoter which may be constitutive or regulated.
Such promoters are well known in the art and include, but are not limited to, RNA
polymerase II promoters, the T7 RNA polymerase promoter, and the RNA
polymerase III promoters U6 and Hl. Viral-mediated delivery includes the use of vectors based on, without limitation, retroviruses, adenoviruses, adeno-associated viruses, vaccinia virus, lentiviruses, polioviruses, and herpesviruses.
The pharmaceutical compositions of the present invention can be administered by any suitable route, for example, by injection (e.g., intravenously, intracerebroventricularly, and intramuscularly), by oral, pulmonary, nasal, rectal, or other modes of administration. The compositions can be administered for the treatment of Huntington's disease which can be treated through the downregulation of htt. The compositions may be used in vitro, in vivo, and/or ex vivo. With regard to ex vivo use, the U1A0 of the instant invention (or compositions comprising the same) may be delivered to autologous cells (optionally comprising the step of obtaining the cells from the subject) and then re-introduced into the subject. The compositions, U1 AO, and/or vectors of the instant invention may also be comprised in a kit.
The instant invention also encompasses methods of treating, inhibiting (slowing or reducing), and/or preventing Huntington's disease in a subject. In a particular embodiment, the methods comprise the administration of a therapeutically effective amount of at least one composition of the instant invention to a subject (e.g., an animal or human) in need thereof In a particular embodiment, the composition comprises at least one U1 AO of the instant invention and at least one 2 0 pharmaceutically acceptable carrier. In a particular embodiment, the U1 AO is directed to htt, particularly htt (e.g., mutant htt) that is full-length and/or truncated.
The instant methods may further comprise the administration of at least one other agent which inhibits the expression of the target htt gene. For example, the method may further comprise the administration of at least one siRNA or anti sense oligonucleotide directed against the htt gene. The methods may also comprise the administration at least one other therapeutic agent (e.g., a symptom-alleviating therapeutic agent for Huntington's disease (e.g., tetrabenazine (Xenazineg) or deutetrabenazine (Austedog)). In a particular embodiment, the therapeutic agent is conjugated to the U1A0 (e.g., directly or via a linker; e.g., at the 3' end and/or 5'end).
The therapeutic agent may be administered in separate compositions (e.g., with at least one pharmaceutically acceptable carrier) or in the same composition. The therapeutic agent may be administered simultaneously and/or consecutively with the U1A0.
As stated hereinabove, the U1 AO of the present invention may be administered alone (as naked polynucleotides) or may be administered with an agent which enhances its uptake by cells. In a particular embodiment, the U1 AO may be contained within a delivery vehicle such as a micelle, liposome, nanoparticle, or polymeric composition. In a particular embodiment, the U1A0 is complexed with (e.g., contained within or encapsulated by) a dendrimer, particularly cationic dendrimers such as poly(amido amine) (PAMAM) dendrimers and polypropyleneimine (PPI) dendrimers (e.g., generation 2, 3, 4, or 5). In a particular embodiment, the U1A0 is complexed with PPI-G2.
1 0 In a particular embodiment, the U1 AO are targeted to a particular cell type (e.g., neurons). In a particular embodiment, the U1A0 is covalently linked (e.g., directly or via a linker) to at least one targeting moiety. The targeting moiety may be operably linked to the 5' end, the 3' end, or both ends or to internal nucleotides. In a particular embodiment, one or more targeting moieties are conjugated to one end of the U1 AO (e.g., through a single linker). In a particular embodiment, a complex comprising the U1A0 (e.g., a dendrimer, micelle, liposome, nanoparticle, or polymeric composition) is covalently linked (e.g., directly or via a linker) to at least one targeting moiety.
Generally, the linker is a chemical moiety comprising a covalent bond or a 2 0 chain of atoms that covalently attaches two compounds such as a targeting moiety to the U1A0 or complex. The linker can be linked to any synthetically feasible position of the targeting moiety and the U1 AO or complex (vehicle). In a particular embodiment, the linker connects the targeting moiety and the U1 AO or complex via an amine group and/or sulfhydryl/thiol group, particularly a sulfhydryl/thiol group.
For example, the U1A0 may be derivatized (e.g., at the 5' end) with one or more amino or thio groups. In a particular embodiment, the linker is attached at a position which avoids blocking the targeting moiety or the activity of the U1 AO.
Exemplary linkers may comprise at least one optionally substituted; saturated or unsaturated;
linear, branched or cyclic alkyl group or an optionally substituted aryl group. The linker may also be a polypeptide (e.g., from about 1 to about 20 amino acids or more, or 1 to about 5). The linker may be biodegradable (cleavable (e.g., comprises a disulfide bond)) under physiological environments or conditions. In a particular embodiment, the linker comprises polyethylene glycol (PEG) (alone or in combination with another linker). In a particular embodiment, the linker is a SPDP
(N-Succinimidyl 3-(2-pyridyldithio)-propionate) linker such as LC- SPDP
(succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate) or a SMCC
(succinimidy1-4-(N-maleimidomethyl) cyclohexane-l-carboxylate) linker such as LC-SMCC(succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate)). The linker may also be non-degradable (non-cleavable) and may be a covalent bond or any other chemical structure which cannot be substantially cleaved or cleaved at all under physiological environments or conditions.
Targeting moieties of the instant invention preferentially bind to the relevant tissue (e.g., nerves) or organ (e.g., brain). In a particular embodiment, the targeting 1 0 moiety specifically binds to a marker specifically (e.g., only) expressed on the target cells or a marker up-regulated on the target cells compared to other cells. In a particular embodiment, the targeting moiety is an antibody or antibody fragment immunologically specific for a surface protein on the target cells or a surface protein expressed at higher levels (or greater density) on the target cells than other cells, tissues, or organs. The antibody or antibody fragment may be a therapeutic antibody (e.g., possessing a therapeutic effect itself). In a particular embodiment, the targeting moiety is a ligand or binding fragment thereof for a cell surface receptor on the target cells. In a particular embodiment, the targeting moiety is an aptamer.
The U1 AO of the instant invention may further be conjugated to other desirable compounds. For example, the U1A0 may be further conjugated (directly or via a linker as described above) to detectable agents, therapeutics (e.g., monoclonal antibodies, peptides, proteins, inhibitory nucleic acid molecules, small molecules, chemotherapeutic agents, etc.), carrier protein, and agents which improve bioavailability, stability, and/or absorption (e.g., PEG). The additional compounds may be attached to any synthetically feasible position of the U1A0 (or conjugate (e.g., to the Ul Adaptor (e.g., either end) or the targeting moiety).
Alternatively, the targeting moiety and the U1 AO are each individually attached to additional compound (e.g., carrier protein) (as such the additional compound can be considered to serve as the linker between the U1 AO and the targeting moiety). In a particular embodiment, the U1A0 is conjugated to a targeting moiety (e.g., neuron targeting moiety) at one end and, optionally, a therapeutic agent on the other.
Preferentially, the attachment of the additional compounds does not significantly affect the activity of the U1 AO or the targeting moiety. Detectable agents may be any compound or protein which may be assayed for directly or indirectly, particularly directly.
Detectable agents include, for example, chemiluminescent, bioluminescent, and/or fluorescent compounds or proteins, imaging agent, contrast agent, radionuclides, paramagnetic or superparamagnetic ions, isotopes (e.g., radioisotopes (e.g., (tritium) and "C) or stable isotopes (e.g., 2H (deuterium), nc, 13C, 170 and 180), optical agents, and fluorescence agents.
Carrier proteins include, without limitation, serum albumin (e.g., bovine, human), ovalbumin, and keyhole limpet hemocyanin (KLH). In a particular embodiment, the carrier protein is human serum albumin. Carrier proteins (as well as other proteins or peptides) may be conjugated to the U1A0 (or conjugate) at any synthetically feasible position. For example, linkers (e.g., LC-SPDP) may be attached to free amino groups found on lysines of the carrier protein and then the U1A0 and targeting moieties may be conjugated to the linkers. Any unreacted linkers may be inactivated by blocking with cysteine.
The U1A0 of the instant invention may be conjugated (e.g., directly or via a linker) to a compound (e.g., antibodies, peptides, proteins, nucleic acid molecules, small molecules, etc.) which targets the U1A0 to a desired cell type and/or promotes cellular uptake of the U1A0 (e.g., a cell penetrating moiety). The targeting moiety may be operably linked to the 5' end, the 3' end, or both ends or to internal nucleotides. In a particular embodiment, the targeting moiety and/or cell penetrating moiety are conjugated to the 5' end and/or 3' end. In a particular embodiment, the targeting moiety and/or cell penetrating moiety is conjugated to the 5' end.
In a particular embodiment, the U1A0 is conjugated to both a targeting moiety and a cell penetrating moiety. As used herein, the term "cell penetrating agent" or "cell penetrating moiety" refers to compounds or functional groups which mediate transfer of a compound from an extracellular space to within a cell. In a particular embodiment, the U1A0 is conjugated to an aptamer. The aptamer may be targeted to a surface compound or protein (e.g., receptor) of a desired cell type (e.g., the surface compound or protein may be preferentially or exclusively expressed on the surface of the cell type to be targeted). In a particular embodiment, the aptamer is a cell penetrating aptamer (e.g., Cl or Otter (see, e.g., Burke, D.H. (2012) Mol.
Ther., 20:
251-253)). In a particular embodiment, the U1 AO is conjugated to a cell penetrating peptide (e.g., Tat peptides (e.g., YGRKKKRRQRRRPPQ; SEQ ID NO: 6 (optionally acetylated on N-terminus)), Penetratin (e.g., RQIKIWFQNRRMKWKKGG; SEQ ID
NO: 7), short amphipathic peptides (e.g., from the Pep- and MPG-families), oligoarginine (e.g., 4-12 consecutive arginine), oligolysine (e.g., 4-12 consecutive lysine)). In a particular embodiment, the U1A0 is conjugated to a small molecule such as biotin (as part of targeting antibodies) or a non-polar fluorescent group (e.g., a cyanine such as Cy3 or Cy5) or to other cell penetrating agents.
In a particular embodiment, at least one of the 3' end and 5' end of the U1A0 comprises a free-SH group.
The U1A0 (including the vehicles comprising the same) described herein will generally be administered to a patient as a pharmaceutical preparation. The terms "patient" and "subject", as used herein, include humans and animals. These Ul adaptors may be employed therapeutically, under the guidance of a physician.
The compositions comprising the U1A0 of the instant invention may be conveniently formulated for administration with any pharmaceutically acceptable carrier(s). For example, the U1 AO may be formulated with an acceptable medium such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof The concentration of the U1A0 in the chosen medium may be varied and the medium may be chosen based on the desired route of administration of the pharmaceutical preparation. Except insofar as any conventional media or agent is incompatible with the U1 AO to be 2 0 administered, its use in the pharmaceutical preparation is contemplated.
The dose and dosage regimen of U1 AO according to the invention that are suitable for administration to a particular patient may be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition for which the U1 AO is being administered and the severity thereof The physician may also take into account the route of administration, the pharmaceutical carrier, and the UlAO's biological activity.
Selection of a suitable pharmaceutical preparation will also depend upon the mode of administration chosen. For example, the U1A0 of the invention may be administered by direct injection to a desired site (e.g., brain). In this instance, a pharmaceutical preparation comprises the U1A0 dispersed in a medium that is compatible with the site of injection. U1 AO of the instant invention may be administered by any method. For example, the U1A0 of the instant invention can be administered, without limitation parenterally, subcutaneously, orally, topically, pulmonarily, rectally, vaginally, intravenously, intracerebroventricularly, intracrani ally, intraperitoneally, intrathecally, intracerebrally, epidurally, intramuscularly, intradermally, or intracarotidly. In a particular embodiment, the method of administration is by direct injection (e.g., into the brain) or intracerebroventricularly. Pharmaceutical preparations for injection are known in the art. If injection is selected as a method for administering the U1 AO, steps should be taken to ensure that sufficient amounts of the molecules or cells reach their target cells to exert a biological effect.
Pharmaceutical compositions containing a U1 AO of the present invention as the active ingredient in intimate admixture with a pharmaceutically acceptable carrier can be prepared according to conventional pharmaceutical compounding techniques.
The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, direct injection, intracranial, intracerebroventricular, and intravitreal.
A pharmaceutical preparation of the invention may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to a physically discrete unit of the pharmaceutical preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate 2 0 dosage unit are well known to those skilled in the art.
Dosage units may be proportionately increased or decreased based on the weight of the patient. Appropriate concentrations for alleviation of a particular pathological condition may be determined by dosage concentration curve calculations, as known in the art.
In accordance with the present invention, the appropriate dosage unit for the administration of U1 AO may be determined by evaluating the toxicity of the molecules or cells in animal models. Various concentrations of U1 AO in pharmaceutical preparations may be administered to mice, and the minimal and maximal dosages may be determined based on the beneficial results and side effects observed as a result of the treatment. Appropriate dosage unit may also be determined by assessing the efficacy of the U1 AO treatment in combination with other standard drugs. The dosage units of U1A0 may be determined individually or in combination with each treatment according to the effect detected.
The pharmaceutical preparation comprising the U1A0 may be administered at appropriate intervals, for example, at least twice a day or more until the pathological symptoms are reduced or alleviated, after which the dosage may be reduced to a maintenance level. The appropriate interval in a particular case would normally depend on the condition of the patient.
Definitions The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
1 0 "Nucleic acid" or a "nucleic acid molecule" as used herein refers to any DNA
or RNA molecule, either single or double stranded and, if single stranded, the molecule of its complementary sequence in either linear or circular form. In discussing nucleic acid molecules, a sequence or structure of a particular nucleic acid molecule may be described herein according to the normal convention of providing the sequence in the 5' to 3' direction. With reference to nucleic acids of the invention, the term "isolated nucleic acid" is sometimes used. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated. For example, an "isolated nucleic acid" may comprise a DNA
molecule 2 0 inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or host organism.
When applied to RNA, the term "isolated nucleic acid" may refer to an RNA
molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues). An isolated nucleic acid (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.
A "vector" is a genetic element, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (either DNA or RNA) may be attached. The vector may be a replicon so as to bring about the replication of the attached sequence or element.
An "expression operon" refers to a nucleic acid segment that may possess transcriptional and translational control sequences, such as promoters, enhancers, translational start signals (e.g., ATG or AUG codons), polyadenylation signals, terminators, and the like, and which facilitate the expression of a nucleic acid or a polypeptide coding sequence in a host cell or organism. An "expression vector"
is a vector which facilitates the expression of a nucleic acid or a polypeptide coding sequence in a host cell or organism.
The term "oligonucleotide," as used herein, refers to nucleic acid sequences, primers, and probes of the present invention, and is defined as a nucleic acid molecule comprised of two or more ribo or deoxyribonucleotides, preferably more than three.
The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide.
The phrase "small, interfering RNA (siRNA)" refers to a short (typically less than 30 nucleotides long, more typically between about 21 to about 25 nucleotides in length) double stranded RNA molecule. Typically, the siRNA modulates the expression of a gene to which the siRNA is targeted. The term "short hairpin RNA"
or "shRNA" refers to an siRNA precursor that is a single RNA molecule folded into a hairpin structure comprising an siRNA and a single stranded loop portion of at least one, typically 1-10, nucleotide.
The term "RNA interference" or "RNAi" refers generally to a sequence-specific or selective process by which a target molecule (e.g., a target gene, protein or RNA) is downregulated via a double-stranded RNA. The double-stranded RNA
structures that typically drive RNAi activity are siRNAs, shRNAs, microRNAs, and other double-stranded structures that can be processed to yield a small RNA
species that inhibits expression of a target transcript by RNA interference.
The term "antisense" refers to an oligonucleotide having a sequence that hybridizes to a target sequence in an RNA by Watson-Crick base pairing, to form an RNA:oligonucleotide heteroduplex with the target sequence, typically with an mRNA. The antisense oligonucleotide may have exact sequence complementarity to the target sequence or near complementarity. These antisense oligonucleotides may block or inhibit translation of the mRNA, and/or modify the processing of an mRNA
to produce a splice variant of the mRNA. Antisense oligonucleotides are typically between about 5 to about 100 nucleotides in length, more typically, between about 7 and about 50 nucleotides in length, and even more typically between about 10 nucleotides and about 30 nucleotides in length.
The term "substantially pure" refers to a preparation comprising at least 50-60% by weight of a given material (e.g., nucleic acid, oligonucleotide, protein, etc.).
More preferably, the preparation comprises at least 75% by weight, and most preferably 90- 95% by weight of the given compound. Purity is measured by methods appropriate for the given compound (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).
The term "isolated" may refer to a compound or complex that has been sufficiently separated from other compounds with which it would naturally be associated. "Isolated" is not meant to exclude artificial or synthetic mixtures with other compounds or materials, or the presence of impurities that do not interfere with fundamental activity or ensuing assays, and that may be present, for example, due to incomplete purification, or the addition of stabilizers.
The term "gene" refers to a nucleic acid comprising an open reading frame encoding a polypeptide, including both exon and (optionally) intron sequences.
The nucleic acid may also optionally include non coding sequences such as promoter or enhancer sequences. The term "intron" refers to a DNA sequence present in a given gene that is not translated into protein and is generally found between exons.
As used herein, the term "aptamer" refers to a nucleic acid that specifically binds to a target, such as a protein, through interactions other than Watson-Crick base 2 0 pairing. In a particular embodiment, the aptamer specifically binds to one or more targets (e.g., a protein or protein complex) to the general exclusion of other molecules in a sample. The aptamer may be a nucleic acid such as an RNA, a DNA, a modified nucleic acid, or a mixture thereof The aptamer may also be a nucleic acid in a linear or circular form and may be single stranded or double stranded. The aptamer may comprise oligonucleotides that are at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40 or more nucleotides in length.
Aptamers may comprise sequences that are up to 40, up to 60, up to 80, up to 100, up to 150, up to 200 or more nucleotides in length. Aptamers may be from about 5 to about 150 nucleotides, from about 10 to about 100 nucleotides, or from about 20 to about nucleotides in length. While aptamers are discussed herein as nucleic acid molecules (e.g., oligonucleotides) aptamers, aptamer equivalents may also be used in place of the nucleic acid aptamers, such as peptide aptamers.
The phrase "operably linked", as used herein, may refer to a nucleic acid sequence placed into a functional relationship with another nucleic acid sequence.
Examples of nucleic acid sequences that may be operably linked include, without limitation, promoters, transcription terminators, enhancers or activators and heterologous genes which when transcribed and, if appropriate to, translated will produce a functional product such as a protein, ribozyme or RNA molecule.
"Pharmaceutically acceptable" indicates approval by a regulatory agency of the Federal government or a state government. "Pharmaceutically acceptable"
agents may be listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
A "carrier" refers to, for example, a diluent, preservative, solubilizer, 1 0 emulsifier, adjuvant, excipient, auxilliary agent or vehicle with which an active agent of the present invention is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
Water or aqueous saline solutions and aqueous dextrose and glycerol solutions may be employed as carriers. Suitable pharmaceutical carriers are described, for example, in "Remington's Pharmaceutical Sciences" by E.W. Martin.
An "antibody" or "antibody molecule" is any immunoglobulin, including antibodies and fragments thereof (e.g., immunologically specific fragments), that binds to a specific antigen. As used herein, antibody or antibody molecule contemplates intact immunoglobulin molecules, immunologically active portions of an immunoglobulin molecule, and fusions of immunologically active portions of an immunoglobulin molecule. The term includes polyclonal, monoclonal, chimeric, single domain (Dab) and bispecific antibodies. As used herein, antibody or antibody molecule contemplates recombinantly generated intact immunoglobulin molecules and immunologically active portions of an immunoglobulin molecule such as, without limitation: Fab, Fab', F(al302, F(v), scFv, scFv2, and scFv-Fc.
With respect to antibodies, the term "immunologically specific" refers to antibodies that bind to one or more epitopes of a protein or compound of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules.
The term "treat" refers to the ability of the compound to relieve, alleviate, and/or slow the progression of the patient's disease. In other words, the term "treat"
refers to inhibiting and/or reversing the progression of a disease.
The following example describes illustrative methods of practicing the instant invention and is not intended to limit the scope of the invention in any way.
EXAMPLE
HD9197 cells (Coriel Institute GM09197; 21/181 CAG repeats, fibroblast 6 year old male) were transfected with a panel of Ul adaptor oligonucleotides (U1A0s) and siRNAs (see below) directed against full length human huntingtin (HTT) using LipofectamineTM RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA). The percent change of human HTT mRNA normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) was determined. As seen in Figure 2, human HTT-full length mRNA-2 (hHTT-FL-2) U1A0 had the highest silencing activity which was significantly greater than the silencing observed with any siRNA.
Notably, further experiments also showed that hHTT-FL-1 U1A0 can silence to <
30%. Similar results were obtained with DU145 (human prostate cancer cell line) and Mia PaCa2 cells (human pancreatic cancer cell line). With regard to the truncated version of HTT (also referred to as the alternatively spliced or intron 1 truncated form), hHTT-TR-1 U1A0 was determined to have the greatest silencing activity.
The U1A0s and siRNA used for the experiments described herein are:
U1A0s:
hHTT-fl-li: UCCUGCUGAUGACAUGUGGGGCCAGGUAAGUAU (SEQ ID NO:
8), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-21: CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO:
9), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-31: CAACCACCUCAAGCACAGACGCCAGGUAAGUAU (SEQ IDNO:
10), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-41: UUCGUAAACAAGUCAGCAGCGCCAGGUAAGUAU (SEQ ID NO:
UCCUGCUGAUGACAUGUGGGGCCAGGUAAGUAU (SEQ ID NO: 8);
CCAGCUUGCCCAUCCUGCUGGCCAGGUAAGUAU (SEQ ID NO: 37);
AGGUUCACGUCCACCUGCUCGCCAGGUAAGUAU (SEQ ID NO: 38);
CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 9);
GUCUGUGGCGACCAGGCAGAGCCAGGUAAGUAU (SEQ ID NO: 39);
CAACCACCUCAAGCACAGACGCCAGGUAAGUAU (SEQ ID NO: 10):
UUCGUAAACAAGUCAGCAGCGCCAGGUAAGUAU (SEQ ID NO: 11);
GCCUCACAGUCUCUCCCACCGCCAGGUAAGUAU (SEQ ID NO: 12);
GUGACUAUCAGGAGAAAGGAGCCAGGUAAGUAU (SEQ ID NO: 13);
CAGAAAAGGTUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 14);
AGGGUTACCGCCATCCCCGCGCCAGGUAAGUAU (SEQ ID NO: 15);
or GCGAGAGGACAAGGGAAGACGCCAGGUAAGUAU (SEQ ID NO: 16).
In a particular embodiment, the U1A0 comprises CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO: 9). In another embodiment, the U1A0 has at least 70%, at least 75%, at least 80%, at least 85%, and more particularly at least 90%, at least 95%, at least 97% or more identity with one of the above sequences or in Figures 14A-14L. With regard to the sequences provided herein, uracil bases and thymidine bases may be exchanged. In a particular embodiment, the U1A0 comprises at least one or all nucleotide analogs. In a particular embodiment, the U1A0 comprises 2'-0-methyl nucleotides, 2'-0-methyloxyethoxy nucleotides, 2'-halo (e.g., 2'-fluoro), and/or locked nucleic acids.
In a particular embodiment, the U1A0 comprises phosphorothioates. In a particular embodiment, the U1A0 are modified as set forth in the Example.
In another embodiment of the instant invention, more than one U1A0 directed to a gene of interest (htt) may be used to modulate expression. Multiple U1A0 targeting (annealing) to different sequences in the same pre-mRNA can provide enhanced inhibition. Compositions of the instant invention may comprise more than one U1A0 directed to the htt gene (e.g., different targets within the htt gene).
In still another embodiment, the U1A0 can be combined with other methods of modulating the expression of a gene of interest. For example, a U1A0 can be used in coordination with other inhibitory nucleic acid molecules such as antisense oligonucleotides or RNase H-based methods, RNAi, miRNA, and morpholino-based methods to give enhanced inhibition. Inasmuch as U1A0 utilize a different mechanism than these other approaches, the combined use will result in an increased inhibition of gene expression compared to the use of a single inhibitory agent alone.
Indeed, U1A0 may target the biosynthetic step in the nucleus whereas RNAi and certain antisense approaches generally target cytoplasmic stability or translatability of a pre-existing pool of mRNA.
In another aspect of the instant invention, the effector domain of the Ul adaptor can be replaced with the binding site for any one of a number of nuclear factors that regulate gene expression. For example, the binding site for polypyrimidine tract binding protein (PTB) is short and PTB is known to inhibit poly(A) sites. Thus, replacing the effector domain with a high affinity PTB
binding site would also silence expression of the target gene.
There are Ul snRNA genes that vary in sequence from the canonical Ul snRNA described hereinabove. Collectively, these Ul snRNA genes can be called the Ul variant genes. Some Ul variant genes are described in GenBank Accession Nos.
L78810, ACO25268, ACO25264 and AL592207 and in Kyriakopoulou et al. (RNA
(2006) 12:1603-11), which identified close to 200 potential Ul snRNA-like genes in the human genome. Since some of these Ul variants have a 5' end sequence different than canonical Ul snRNA, one plausible function is to recognize alternative splice signals during pre-mRNA splicing. Accordingly, the Ul domain of the U1A0 of the instant invention may be designed to hybridize with the 5' end of the Ul variant snRNA in the same way as the Ul domain was designed to hybridize with the canonical Ul snRNA as described herein. The U1A0 which hybridize to the Ul variants may then be used to modulate the expression of a gene of interest.
There are many advantages of the Ul adaptor technology to other existing silencing technologies. Certain of these advantages are as follows. First, the separates into two independent domains: (1) the annealing (i.e., targeting) activity and (2) the inhibitory activity, thereby allowing one to optimize annealing without affecting the inhibitory activity or vice versa. Second, as compared to other technologies, usage of two U1A0 to target the same gene gives additive even synergistic inhibition. Third, the U1A0 has a novel inhibitory mechanism.
Therefore, it will be compatible when used in combination with other methods.
Fourth, the U1 AO inhibits the biosynthesis of mRNA by inhibiting the critical, nearly-universal, pre-mRNA maturation step of poly(A) tail addition (also called 3' end processing).
Compositions of the instant invention comprise at least one U1 AO of the instant invention and at least one pharmaceutically acceptable carrier. The compositions may further comprise at least one other agent which inhibits the expression of the gene of interest (htt). For example, the composition may further 2 0 comprise at least one siRNA or antisense oligonucleotide directed against the gene of interest (htt).
The U1A0 of the present invention may be administered alone, as naked polynucleotides, to cells or an organism, including animals and humans. The may be administered with an agent which enhances its uptake by cells. In a particular embodiment, the U1A0 may be contained within a liposome, nanoparticle, or polymeric composition.
In another embodiment, the U1A0 may be delivered to a cell or animal, including humans, in an expression vector such as a plasmid or viral vector.
For example, a U1A0 can be expressed from a vector such as a plasmid or a virus.
Expression of such short RNAs from a plasmid or virus has become routine and can be easily adapted to express a U1A0. Expression vectors for the expression of RNA
molecules may employ a strong promoter which may be constitutive or regulated.
Such promoters are well known in the art and include, but are not limited to, RNA
polymerase II promoters, the T7 RNA polymerase promoter, and the RNA
polymerase III promoters U6 and Hl. Viral-mediated delivery includes the use of vectors based on, without limitation, retroviruses, adenoviruses, adeno-associated viruses, vaccinia virus, lentiviruses, polioviruses, and herpesviruses.
The pharmaceutical compositions of the present invention can be administered by any suitable route, for example, by injection (e.g., intravenously, intracerebroventricularly, and intramuscularly), by oral, pulmonary, nasal, rectal, or other modes of administration. The compositions can be administered for the treatment of Huntington's disease which can be treated through the downregulation of htt. The compositions may be used in vitro, in vivo, and/or ex vivo. With regard to ex vivo use, the U1A0 of the instant invention (or compositions comprising the same) may be delivered to autologous cells (optionally comprising the step of obtaining the cells from the subject) and then re-introduced into the subject. The compositions, U1 AO, and/or vectors of the instant invention may also be comprised in a kit.
The instant invention also encompasses methods of treating, inhibiting (slowing or reducing), and/or preventing Huntington's disease in a subject. In a particular embodiment, the methods comprise the administration of a therapeutically effective amount of at least one composition of the instant invention to a subject (e.g., an animal or human) in need thereof In a particular embodiment, the composition comprises at least one U1 AO of the instant invention and at least one 2 0 pharmaceutically acceptable carrier. In a particular embodiment, the U1 AO is directed to htt, particularly htt (e.g., mutant htt) that is full-length and/or truncated.
The instant methods may further comprise the administration of at least one other agent which inhibits the expression of the target htt gene. For example, the method may further comprise the administration of at least one siRNA or anti sense oligonucleotide directed against the htt gene. The methods may also comprise the administration at least one other therapeutic agent (e.g., a symptom-alleviating therapeutic agent for Huntington's disease (e.g., tetrabenazine (Xenazineg) or deutetrabenazine (Austedog)). In a particular embodiment, the therapeutic agent is conjugated to the U1A0 (e.g., directly or via a linker; e.g., at the 3' end and/or 5'end).
The therapeutic agent may be administered in separate compositions (e.g., with at least one pharmaceutically acceptable carrier) or in the same composition. The therapeutic agent may be administered simultaneously and/or consecutively with the U1A0.
As stated hereinabove, the U1 AO of the present invention may be administered alone (as naked polynucleotides) or may be administered with an agent which enhances its uptake by cells. In a particular embodiment, the U1 AO may be contained within a delivery vehicle such as a micelle, liposome, nanoparticle, or polymeric composition. In a particular embodiment, the U1A0 is complexed with (e.g., contained within or encapsulated by) a dendrimer, particularly cationic dendrimers such as poly(amido amine) (PAMAM) dendrimers and polypropyleneimine (PPI) dendrimers (e.g., generation 2, 3, 4, or 5). In a particular embodiment, the U1A0 is complexed with PPI-G2.
1 0 In a particular embodiment, the U1 AO are targeted to a particular cell type (e.g., neurons). In a particular embodiment, the U1A0 is covalently linked (e.g., directly or via a linker) to at least one targeting moiety. The targeting moiety may be operably linked to the 5' end, the 3' end, or both ends or to internal nucleotides. In a particular embodiment, one or more targeting moieties are conjugated to one end of the U1 AO (e.g., through a single linker). In a particular embodiment, a complex comprising the U1A0 (e.g., a dendrimer, micelle, liposome, nanoparticle, or polymeric composition) is covalently linked (e.g., directly or via a linker) to at least one targeting moiety.
Generally, the linker is a chemical moiety comprising a covalent bond or a 2 0 chain of atoms that covalently attaches two compounds such as a targeting moiety to the U1A0 or complex. The linker can be linked to any synthetically feasible position of the targeting moiety and the U1 AO or complex (vehicle). In a particular embodiment, the linker connects the targeting moiety and the U1 AO or complex via an amine group and/or sulfhydryl/thiol group, particularly a sulfhydryl/thiol group.
For example, the U1A0 may be derivatized (e.g., at the 5' end) with one or more amino or thio groups. In a particular embodiment, the linker is attached at a position which avoids blocking the targeting moiety or the activity of the U1 AO.
Exemplary linkers may comprise at least one optionally substituted; saturated or unsaturated;
linear, branched or cyclic alkyl group or an optionally substituted aryl group. The linker may also be a polypeptide (e.g., from about 1 to about 20 amino acids or more, or 1 to about 5). The linker may be biodegradable (cleavable (e.g., comprises a disulfide bond)) under physiological environments or conditions. In a particular embodiment, the linker comprises polyethylene glycol (PEG) (alone or in combination with another linker). In a particular embodiment, the linker is a SPDP
(N-Succinimidyl 3-(2-pyridyldithio)-propionate) linker such as LC- SPDP
(succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate) or a SMCC
(succinimidy1-4-(N-maleimidomethyl) cyclohexane-l-carboxylate) linker such as LC-SMCC(succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate)). The linker may also be non-degradable (non-cleavable) and may be a covalent bond or any other chemical structure which cannot be substantially cleaved or cleaved at all under physiological environments or conditions.
Targeting moieties of the instant invention preferentially bind to the relevant tissue (e.g., nerves) or organ (e.g., brain). In a particular embodiment, the targeting 1 0 moiety specifically binds to a marker specifically (e.g., only) expressed on the target cells or a marker up-regulated on the target cells compared to other cells. In a particular embodiment, the targeting moiety is an antibody or antibody fragment immunologically specific for a surface protein on the target cells or a surface protein expressed at higher levels (or greater density) on the target cells than other cells, tissues, or organs. The antibody or antibody fragment may be a therapeutic antibody (e.g., possessing a therapeutic effect itself). In a particular embodiment, the targeting moiety is a ligand or binding fragment thereof for a cell surface receptor on the target cells. In a particular embodiment, the targeting moiety is an aptamer.
The U1 AO of the instant invention may further be conjugated to other desirable compounds. For example, the U1A0 may be further conjugated (directly or via a linker as described above) to detectable agents, therapeutics (e.g., monoclonal antibodies, peptides, proteins, inhibitory nucleic acid molecules, small molecules, chemotherapeutic agents, etc.), carrier protein, and agents which improve bioavailability, stability, and/or absorption (e.g., PEG). The additional compounds may be attached to any synthetically feasible position of the U1A0 (or conjugate (e.g., to the Ul Adaptor (e.g., either end) or the targeting moiety).
Alternatively, the targeting moiety and the U1 AO are each individually attached to additional compound (e.g., carrier protein) (as such the additional compound can be considered to serve as the linker between the U1 AO and the targeting moiety). In a particular embodiment, the U1A0 is conjugated to a targeting moiety (e.g., neuron targeting moiety) at one end and, optionally, a therapeutic agent on the other.
Preferentially, the attachment of the additional compounds does not significantly affect the activity of the U1 AO or the targeting moiety. Detectable agents may be any compound or protein which may be assayed for directly or indirectly, particularly directly.
Detectable agents include, for example, chemiluminescent, bioluminescent, and/or fluorescent compounds or proteins, imaging agent, contrast agent, radionuclides, paramagnetic or superparamagnetic ions, isotopes (e.g., radioisotopes (e.g., (tritium) and "C) or stable isotopes (e.g., 2H (deuterium), nc, 13C, 170 and 180), optical agents, and fluorescence agents.
Carrier proteins include, without limitation, serum albumin (e.g., bovine, human), ovalbumin, and keyhole limpet hemocyanin (KLH). In a particular embodiment, the carrier protein is human serum albumin. Carrier proteins (as well as other proteins or peptides) may be conjugated to the U1A0 (or conjugate) at any synthetically feasible position. For example, linkers (e.g., LC-SPDP) may be attached to free amino groups found on lysines of the carrier protein and then the U1A0 and targeting moieties may be conjugated to the linkers. Any unreacted linkers may be inactivated by blocking with cysteine.
The U1A0 of the instant invention may be conjugated (e.g., directly or via a linker) to a compound (e.g., antibodies, peptides, proteins, nucleic acid molecules, small molecules, etc.) which targets the U1A0 to a desired cell type and/or promotes cellular uptake of the U1A0 (e.g., a cell penetrating moiety). The targeting moiety may be operably linked to the 5' end, the 3' end, or both ends or to internal nucleotides. In a particular embodiment, the targeting moiety and/or cell penetrating moiety are conjugated to the 5' end and/or 3' end. In a particular embodiment, the targeting moiety and/or cell penetrating moiety is conjugated to the 5' end.
In a particular embodiment, the U1A0 is conjugated to both a targeting moiety and a cell penetrating moiety. As used herein, the term "cell penetrating agent" or "cell penetrating moiety" refers to compounds or functional groups which mediate transfer of a compound from an extracellular space to within a cell. In a particular embodiment, the U1A0 is conjugated to an aptamer. The aptamer may be targeted to a surface compound or protein (e.g., receptor) of a desired cell type (e.g., the surface compound or protein may be preferentially or exclusively expressed on the surface of the cell type to be targeted). In a particular embodiment, the aptamer is a cell penetrating aptamer (e.g., Cl or Otter (see, e.g., Burke, D.H. (2012) Mol.
Ther., 20:
251-253)). In a particular embodiment, the U1 AO is conjugated to a cell penetrating peptide (e.g., Tat peptides (e.g., YGRKKKRRQRRRPPQ; SEQ ID NO: 6 (optionally acetylated on N-terminus)), Penetratin (e.g., RQIKIWFQNRRMKWKKGG; SEQ ID
NO: 7), short amphipathic peptides (e.g., from the Pep- and MPG-families), oligoarginine (e.g., 4-12 consecutive arginine), oligolysine (e.g., 4-12 consecutive lysine)). In a particular embodiment, the U1A0 is conjugated to a small molecule such as biotin (as part of targeting antibodies) or a non-polar fluorescent group (e.g., a cyanine such as Cy3 or Cy5) or to other cell penetrating agents.
In a particular embodiment, at least one of the 3' end and 5' end of the U1A0 comprises a free-SH group.
The U1A0 (including the vehicles comprising the same) described herein will generally be administered to a patient as a pharmaceutical preparation. The terms "patient" and "subject", as used herein, include humans and animals. These Ul adaptors may be employed therapeutically, under the guidance of a physician.
The compositions comprising the U1A0 of the instant invention may be conveniently formulated for administration with any pharmaceutically acceptable carrier(s). For example, the U1 AO may be formulated with an acceptable medium such as water, buffered saline, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), dimethyl sulfoxide (DMSO), oils, detergents, suspending agents or suitable mixtures thereof The concentration of the U1A0 in the chosen medium may be varied and the medium may be chosen based on the desired route of administration of the pharmaceutical preparation. Except insofar as any conventional media or agent is incompatible with the U1 AO to be 2 0 administered, its use in the pharmaceutical preparation is contemplated.
The dose and dosage regimen of U1 AO according to the invention that are suitable for administration to a particular patient may be determined by a physician considering the patient's age, sex, weight, general medical condition, and the specific condition for which the U1 AO is being administered and the severity thereof The physician may also take into account the route of administration, the pharmaceutical carrier, and the UlAO's biological activity.
Selection of a suitable pharmaceutical preparation will also depend upon the mode of administration chosen. For example, the U1A0 of the invention may be administered by direct injection to a desired site (e.g., brain). In this instance, a pharmaceutical preparation comprises the U1A0 dispersed in a medium that is compatible with the site of injection. U1 AO of the instant invention may be administered by any method. For example, the U1A0 of the instant invention can be administered, without limitation parenterally, subcutaneously, orally, topically, pulmonarily, rectally, vaginally, intravenously, intracerebroventricularly, intracrani ally, intraperitoneally, intrathecally, intracerebrally, epidurally, intramuscularly, intradermally, or intracarotidly. In a particular embodiment, the method of administration is by direct injection (e.g., into the brain) or intracerebroventricularly. Pharmaceutical preparations for injection are known in the art. If injection is selected as a method for administering the U1 AO, steps should be taken to ensure that sufficient amounts of the molecules or cells reach their target cells to exert a biological effect.
Pharmaceutical compositions containing a U1 AO of the present invention as the active ingredient in intimate admixture with a pharmaceutically acceptable carrier can be prepared according to conventional pharmaceutical compounding techniques.
The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, direct injection, intracranial, intracerebroventricular, and intravitreal.
A pharmaceutical preparation of the invention may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to a physically discrete unit of the pharmaceutical preparation appropriate for the patient undergoing treatment. Each dosage should contain a quantity of active ingredient calculated to produce the desired effect in association with the selected pharmaceutical carrier. Procedures for determining the appropriate 2 0 dosage unit are well known to those skilled in the art.
Dosage units may be proportionately increased or decreased based on the weight of the patient. Appropriate concentrations for alleviation of a particular pathological condition may be determined by dosage concentration curve calculations, as known in the art.
In accordance with the present invention, the appropriate dosage unit for the administration of U1 AO may be determined by evaluating the toxicity of the molecules or cells in animal models. Various concentrations of U1 AO in pharmaceutical preparations may be administered to mice, and the minimal and maximal dosages may be determined based on the beneficial results and side effects observed as a result of the treatment. Appropriate dosage unit may also be determined by assessing the efficacy of the U1 AO treatment in combination with other standard drugs. The dosage units of U1A0 may be determined individually or in combination with each treatment according to the effect detected.
The pharmaceutical preparation comprising the U1A0 may be administered at appropriate intervals, for example, at least twice a day or more until the pathological symptoms are reduced or alleviated, after which the dosage may be reduced to a maintenance level. The appropriate interval in a particular case would normally depend on the condition of the patient.
Definitions The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
1 0 "Nucleic acid" or a "nucleic acid molecule" as used herein refers to any DNA
or RNA molecule, either single or double stranded and, if single stranded, the molecule of its complementary sequence in either linear or circular form. In discussing nucleic acid molecules, a sequence or structure of a particular nucleic acid molecule may be described herein according to the normal convention of providing the sequence in the 5' to 3' direction. With reference to nucleic acids of the invention, the term "isolated nucleic acid" is sometimes used. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated. For example, an "isolated nucleic acid" may comprise a DNA
molecule 2 0 inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or host organism.
When applied to RNA, the term "isolated nucleic acid" may refer to an RNA
molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues). An isolated nucleic acid (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.
A "vector" is a genetic element, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (either DNA or RNA) may be attached. The vector may be a replicon so as to bring about the replication of the attached sequence or element.
An "expression operon" refers to a nucleic acid segment that may possess transcriptional and translational control sequences, such as promoters, enhancers, translational start signals (e.g., ATG or AUG codons), polyadenylation signals, terminators, and the like, and which facilitate the expression of a nucleic acid or a polypeptide coding sequence in a host cell or organism. An "expression vector"
is a vector which facilitates the expression of a nucleic acid or a polypeptide coding sequence in a host cell or organism.
The term "oligonucleotide," as used herein, refers to nucleic acid sequences, primers, and probes of the present invention, and is defined as a nucleic acid molecule comprised of two or more ribo or deoxyribonucleotides, preferably more than three.
The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide.
The phrase "small, interfering RNA (siRNA)" refers to a short (typically less than 30 nucleotides long, more typically between about 21 to about 25 nucleotides in length) double stranded RNA molecule. Typically, the siRNA modulates the expression of a gene to which the siRNA is targeted. The term "short hairpin RNA"
or "shRNA" refers to an siRNA precursor that is a single RNA molecule folded into a hairpin structure comprising an siRNA and a single stranded loop portion of at least one, typically 1-10, nucleotide.
The term "RNA interference" or "RNAi" refers generally to a sequence-specific or selective process by which a target molecule (e.g., a target gene, protein or RNA) is downregulated via a double-stranded RNA. The double-stranded RNA
structures that typically drive RNAi activity are siRNAs, shRNAs, microRNAs, and other double-stranded structures that can be processed to yield a small RNA
species that inhibits expression of a target transcript by RNA interference.
The term "antisense" refers to an oligonucleotide having a sequence that hybridizes to a target sequence in an RNA by Watson-Crick base pairing, to form an RNA:oligonucleotide heteroduplex with the target sequence, typically with an mRNA. The antisense oligonucleotide may have exact sequence complementarity to the target sequence or near complementarity. These antisense oligonucleotides may block or inhibit translation of the mRNA, and/or modify the processing of an mRNA
to produce a splice variant of the mRNA. Antisense oligonucleotides are typically between about 5 to about 100 nucleotides in length, more typically, between about 7 and about 50 nucleotides in length, and even more typically between about 10 nucleotides and about 30 nucleotides in length.
The term "substantially pure" refers to a preparation comprising at least 50-60% by weight of a given material (e.g., nucleic acid, oligonucleotide, protein, etc.).
More preferably, the preparation comprises at least 75% by weight, and most preferably 90- 95% by weight of the given compound. Purity is measured by methods appropriate for the given compound (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).
The term "isolated" may refer to a compound or complex that has been sufficiently separated from other compounds with which it would naturally be associated. "Isolated" is not meant to exclude artificial or synthetic mixtures with other compounds or materials, or the presence of impurities that do not interfere with fundamental activity or ensuing assays, and that may be present, for example, due to incomplete purification, or the addition of stabilizers.
The term "gene" refers to a nucleic acid comprising an open reading frame encoding a polypeptide, including both exon and (optionally) intron sequences.
The nucleic acid may also optionally include non coding sequences such as promoter or enhancer sequences. The term "intron" refers to a DNA sequence present in a given gene that is not translated into protein and is generally found between exons.
As used herein, the term "aptamer" refers to a nucleic acid that specifically binds to a target, such as a protein, through interactions other than Watson-Crick base 2 0 pairing. In a particular embodiment, the aptamer specifically binds to one or more targets (e.g., a protein or protein complex) to the general exclusion of other molecules in a sample. The aptamer may be a nucleic acid such as an RNA, a DNA, a modified nucleic acid, or a mixture thereof The aptamer may also be a nucleic acid in a linear or circular form and may be single stranded or double stranded. The aptamer may comprise oligonucleotides that are at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40 or more nucleotides in length.
Aptamers may comprise sequences that are up to 40, up to 60, up to 80, up to 100, up to 150, up to 200 or more nucleotides in length. Aptamers may be from about 5 to about 150 nucleotides, from about 10 to about 100 nucleotides, or from about 20 to about nucleotides in length. While aptamers are discussed herein as nucleic acid molecules (e.g., oligonucleotides) aptamers, aptamer equivalents may also be used in place of the nucleic acid aptamers, such as peptide aptamers.
The phrase "operably linked", as used herein, may refer to a nucleic acid sequence placed into a functional relationship with another nucleic acid sequence.
Examples of nucleic acid sequences that may be operably linked include, without limitation, promoters, transcription terminators, enhancers or activators and heterologous genes which when transcribed and, if appropriate to, translated will produce a functional product such as a protein, ribozyme or RNA molecule.
"Pharmaceutically acceptable" indicates approval by a regulatory agency of the Federal government or a state government. "Pharmaceutically acceptable"
agents may be listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
A "carrier" refers to, for example, a diluent, preservative, solubilizer, 1 0 emulsifier, adjuvant, excipient, auxilliary agent or vehicle with which an active agent of the present invention is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
Water or aqueous saline solutions and aqueous dextrose and glycerol solutions may be employed as carriers. Suitable pharmaceutical carriers are described, for example, in "Remington's Pharmaceutical Sciences" by E.W. Martin.
An "antibody" or "antibody molecule" is any immunoglobulin, including antibodies and fragments thereof (e.g., immunologically specific fragments), that binds to a specific antigen. As used herein, antibody or antibody molecule contemplates intact immunoglobulin molecules, immunologically active portions of an immunoglobulin molecule, and fusions of immunologically active portions of an immunoglobulin molecule. The term includes polyclonal, monoclonal, chimeric, single domain (Dab) and bispecific antibodies. As used herein, antibody or antibody molecule contemplates recombinantly generated intact immunoglobulin molecules and immunologically active portions of an immunoglobulin molecule such as, without limitation: Fab, Fab', F(al302, F(v), scFv, scFv2, and scFv-Fc.
With respect to antibodies, the term "immunologically specific" refers to antibodies that bind to one or more epitopes of a protein or compound of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules.
The term "treat" refers to the ability of the compound to relieve, alleviate, and/or slow the progression of the patient's disease. In other words, the term "treat"
refers to inhibiting and/or reversing the progression of a disease.
The following example describes illustrative methods of practicing the instant invention and is not intended to limit the scope of the invention in any way.
EXAMPLE
HD9197 cells (Coriel Institute GM09197; 21/181 CAG repeats, fibroblast 6 year old male) were transfected with a panel of Ul adaptor oligonucleotides (U1A0s) and siRNAs (see below) directed against full length human huntingtin (HTT) using LipofectamineTM RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA). The percent change of human HTT mRNA normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) was determined. As seen in Figure 2, human HTT-full length mRNA-2 (hHTT-FL-2) U1A0 had the highest silencing activity which was significantly greater than the silencing observed with any siRNA.
Notably, further experiments also showed that hHTT-FL-1 U1A0 can silence to <
30%. Similar results were obtained with DU145 (human prostate cancer cell line) and Mia PaCa2 cells (human pancreatic cancer cell line). With regard to the truncated version of HTT (also referred to as the alternatively spliced or intron 1 truncated form), hHTT-TR-1 U1A0 was determined to have the greatest silencing activity.
The U1A0s and siRNA used for the experiments described herein are:
U1A0s:
hHTT-fl-li: UCCUGCUGAUGACAUGUGGGGCCAGGUAAGUAU (SEQ ID NO:
8), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-21: CAGAAAAGGUUCACGUCCACGCCAGGUAAGUAU (SEQ ID NO:
9), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-31: CAACCACCUCAAGCACAGACGCCAGGUAAGUAU (SEQ IDNO:
10), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-41: UUCGUAAACAAGUCAGCAGCGCCAGGUAAGUAU (SEQ ID NO:
11), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-51: GCCUCACAGUCUCUCCCACCGCCAGGUAAGUAU (SEQ ID NO:
hHTT-fl-51: GCCUCACAGUCUCUCCCACCGCCAGGUAAGUAU (SEQ ID NO:
12), wherein each nucleotide is 2'-0-methyl;
hHTT-fl-61: GUGACUAUCAGGAGAAAGGAGCCAGGUAAGUAU (SEQ ID NO:
hHTT-fl-61: GUGACUAUCAGGAGAAAGGAGCCAGGUAAGUAU (SEQ ID NO:
13), wherein each nucleotide is 2'-0-methyl;
hHTT-FL-2: mC+AmGmAmA+AmAmGmG+TmUmCmA+CmGmUmC+CmAmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 14), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
hHTT-TR-1: mA+GmGmGmU+TmAmCmC+GmCmCmA+TmCmCmC+CmGmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 15), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
hHTT-TR-2: mGmC+GmAmGmA+GmGmAmC+AmAmGmG+GmAmAmG+AmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 16), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
NC-a (ctrl): mAAmCmGmGmUmUmAmGmGmCmAmCmCmTmCmUmUmGmA
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 17), wherein m = 2'-0-methyl;
mHTT-FL-A: mUmGmC+AmGmCmC+AmCmCmA+CmCmUmC+AmAmAmC+A
mGmCmC+AmGmG+TmA+AmGmU+AmU (SEQ ID NO: 18), wherein m = 2'-0-methyl and + = Locked Nucleic Acid; and mHTT-TR-A: mA+GmUmUmC+TmCmUmU+CmAmCmA+AmCmAmG+TmCmA
mGmCmC+AmGmG+TmA+AmGmU+AmU (SEQ ID NO: 19), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
siRNA:
hHTT-siRNA-1 (both strands presented; r = RNA):
5'-rGrGrA rUrArG rUrArG rArCrA rGrCrA rArUrA rArCrU rCrGG T-3' (SEQ ID NO: 20) 5'-rArCrC rGrArG rUrUrA rUrUrG rCrUrG rUrCrU rArCrU rArUrC rCrGrU-3' (SEQ ID NO: 21);
hHTT-siRNA-2 (both strands presented; r = RNA):
5'-rArGrA rArCrU rUrUrC rArGrC rUrArC rCrArA rGrArA rArGA C-3' (SEQ ID NO: 22) 5'-rGrUrC rUrUrU rCrUrU rGrGrU rArGrC rUrGrA rArArG rUrUrC rUrUrU-3' (SEQ ID NO: 23); and hHTT-siRNA-3 (both strands presented; r = RNA):
5'-rArCrA rGrCrU rCrCrA rGrCrC rArGrG rUrCrA rGrCrG rCrCG T-3' (SEQ ID NO: 24) 5'-rArCrGr GrCrG rCrTrG rArCrC rTrGrG rCrTrG rGrArG rCrTrG rTrTrG-3' (SEQ ID NO: 25).
Figure 3 provides a Western blot of Human DU145 cells transfected 48 hours (LipofectamineTM 2000) with various anti-hHTT-FL Ul AOs and siRNAs (see below).
Cells were lysed directly into laemmli buffer and then analyzed by Western blot after electrophoresis on a 6-20% gradient gel. The best anti-hHTT-FL Ul AOs (hHTT-FL-1 and hHTT-FL-2) were used here and show silencing activity at the protein level.
The anti-HTT-FL siRNA also showed silencing activity. Notably, using less U1A0 gave less silencing (compare lane 9 with lane 7).
YAC128 are mice containing the entire human HTT gene (300,000 bp) having 128 CAG repeats. To determine the effectiveness of the U1A0, either 1 or 20 of hHTT-FL-2 U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into YAC128 mice. After 48 hours, mice were sacrificed with perfusion. Total RNA
from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 4A, a 20 tg unilaterally-ICV-injected dose of the hHTT-FL-2 silences with a 62% reduction of the hHTT-F1 mRNA in YAC128 brain as compared to saline treated mice. The specificity of silencing is confirmed by the fact that neither the hHTT-Tr mRNA isoform (Fig. 4B) nor the Eif4a3 housekeeping gene underwent an observable change in expression.
Total RNA (4 tg /lane) from forebrains of YAC128 mice were analyzed by 32P Northern blot (8% PAGE) (Figure 5). Specifically, the blot was probed with a 33nt 32P-anti-hHTT-FL-2 oligonucleotide complementary to hHTT-FL-2 U1A0 in order to measure U1 AO levels. The lanes marked "Standards" are the uninjected U1A0 and their inclusion allows for a rigorous quantitation. As seen in Figure 5, the U1A0 in the brain tissue is neither degraded nor shortened. Shortening of the injected U1 AO, even by just a few nucleotides, would result in a noticeable change in migration relative to the standards.
An RNAScopeg analysis, a type of in situ hybridization (ISH) technology, was used to detect hHTT-FL transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to hHTT-FL mRNA. As seen in Figure 6, the hHTT-FL-2 U1 AO-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of hHTT-FL.
To further demonstrate the stability of hHTT-FL-2 U1 AO, 20 tg of hHTT-FL-2 U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into YAC128 mice. After 2, 4, or 7 days, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 7A, a 2011g unilaterally-ICV-injected dose of the hHTT-FL-2 U1 AO reduces hHTT-F1 mRNA in YAC128 brain constantly over time. Figure 7B
provides a Northern blot analysis probed with a 33nt32P-anti-hHTT-FL-2 oligonucleotide complementary to hHTT-FL-2 U1 AO in order to measure U1 AO
levels. As seen in Figure 7B, the U1 AO in the brain tissue is neither degraded nor shortened over time.
The ability to silence hHTT-Tr has also been demonstrated. 20 tg of hHTT-1 5 TR-1 U1A0, hHTT-TR-2 U1A0, or saline was unilaterally ICV injected into YAC128 mice. After 48 hours, mice were sacrificed with perfusion. Total RNA
from forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 8A, hHTT-TR-1 U1A0 did not effectively silence hHTT-TR whereas the hHTT-TR-2 U1A0 significantly silences hHTT-TR by about 79%. The effect was specific as no silencing was observed for the hHTT-FL mRNA in either the saline-treated or hHTT-TR-treated mice (Fig. 8B).
Anti-mouse HTT Ul AOs were also synthesized and shown to silence mHTT
in cultured cells. The best anti-mouse HTT Ul AOs were mHTT-TR-a (targeting mHTT-TR mRNA transcript) and mHTT-FL-a (targeting mHTT-FL mRNA
transcript). These Ul AOs were then tested in the Q175 mouse model. Q175 mice are a knock-in mice where, for heterozygotes, one of the HTT alleles has 175 CAG
repeat. To determine the effectiveness of the U1A0, saline, 20 of mHTT-TR-A
U1 AO, or 40 tg of non-specific control adaptor (NC-A) U1 AO was unilaterally ICV
injected into Q175 mice. The NC-A U1A0 is a non-specific control U1A0 designed to not silence any mouse gene. After 48 hours, mice were sacrificed with perfusion.
Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor (Eif4a3). As seen in Figure 9A, a 20 tg unilaterally-ICV-injected dose of the mHTT-TR-A U1A0 silences with a 75% reduction of the mHTT-TR mRNA in Q175 brain as compared to control treated mice. The specificity of silencing is confirmed by the fact that neither the mHTT-FL mRNA isoform (Fig. 9B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
An RNAScopeg analysis was also performed to detect mHTT-TR transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to mHTT-TR mRNA. As seen in Figure 10, the mHTT-TR-A U1 AO-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of mHTT-TR.
To further demonstrate the stability of mHTT-TR-A U1 AO, 20 tg of mHTT-1 5 TR-A U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into Q175 mice. After 21 days, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR
and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3). As seen in Figure 11A, a 20 tg unilaterally-ICV-injected dose of the mHTT-TR-A U1 AO
reduces mHTT-TR mRNA in Q175 mouse brain even after 21 days. The specificity of silencing is confirmed by the fact that neither the mHTT-FL mRNA isoform (Fig.
11B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
To determine the effectiveness of the mHTT-FL U1A0, saline, 40 tg of mHTT-FL-A U1 AO, or 40 tg of non-specific control adaptor (NC-A) U1 AO was unilaterally ICV injected into Q175 mice. The NC-A U1A0 is a non-specific control U1A0 designed to not silence any mouse gene. After 48 hours, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3). As seen in Figure 12A, a 40 unilaterally-ICV-injected dose of the mHTT-FL-A U1A0 silences with a 69% reduction of the mHTT-FL mRNA in Q175 brain as compared to control treated mice. The specificity of silencing is confirmed by the fact that neither the mHTT-TR mRNA isoform (Fig.
12B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
An RNAScopeg analysis was also performed to detect mHTT-FL transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to mHTT-FL mRNA. As seen in Figure 13, the mHTT-FL-A U1A0-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of mHTT-FL.
Biodistribution studies for hHTT-FL-2 U1A0 were also performed. Briefly, to assess biodistribution in brain regions at the single cell level, a series of experiments was performed with a Cy3-fluorescently labelled hHTT-FL-2 U1A0 (Cy3-hHTT-FL-2 U1A0). 5 ig of Cy3-hHTT-FL-2 U1A0 was unilaterally ICV-inj ected into 6-8 month old YAC128 mice. At 1, 7, and 28 days post-injection, mice were sacrificed with perfusion (with saline) to remove blood and extracellular U1A0.
Brain samples were subsequently studied by confocal microscopy. Notably, higher doses of Cy3-hHTT-FL-2 U1 AO were not used because the Cy3 fluorescent group itself proved toxic. Indeed, the injection of 1.5 and 4 of free Cy3, which is the stoichiometric equivalent of 30 tg and 80 tg Cy3-hHTT-FL-2 U1A0, respectively, was determined to be highly toxic to YAC128 mice. The use of 5 tg of Cy3-hHTT-FL-2 U1A0 resulted in no overt toxic effects in YAC128 mice.
The biodistribution assays showed that after Cy3-hHTT-FL-2 U1 AO was ICV-injected into the left ventricle, Cy3-hHTT-FL-2 U1A0 rapidly (within 1 day) and significantly distributed across both left and right hemibrains, resulting in symmetric distribution of Cy3-hHTT-FL-2 U1 AO in both the left and right side of the brain by days 7 and 28. These results show that Cy3-hHTT-FL-2 U1A0 quickly migrates from the left-ventricle injection site into other brain regions (e.g., striatum, cortex, hippocampus, cerebellum), including right hemibrain regions that are farthest from the injection site. Cy3-hHTT-FL-2 U1 AO also had widespread uptake by most neurons (e.g., cortical neurons) and cell types. Additionally, Cy3-hHTT-FL-2 was clearly visible in the nucleus and perinucleus. Lastly, fluorescent intensity was only slightly diminished at the 28 day time point as compared to the 1 and 7 day time points, thereby demonstrating the stability of Cy3-hHTT-FL-2 U1 AO over time.
Further experiments were performed to demonstrate 50% to 80% sustained reduction of the mHTT-F1 transcript from one to four months. In parallel experiments, conditions were identified that achieved 50% to 80% sustained reduction of the mHTT-Tr transcript from one to four months.
First, Q175 mice underwent a single unilateral ICV dose with the mHTT-FL-a U1A0 at four different concentrations - 10, 20, 40, and 80 i.tg (mice n = 9 per dose) -giving 36 mice in total. A cohort of three mice from each concentration was euthanized after 1, 2, and 4 months where mice underwent perfusion with lx PBS
and then sacrificed. Hemibrains were collected and processed for analysis by RT-qPCR
and Northern blot. All Ul Adaptor treated mice were compared to untreated Q175 mice. Silencing of the mHTT-F1 transcript was assessed by RT-qPCR which were then compared to untreated mice set to 100%. RT-qPCR to detect mHTT-Tr transcript included Dnase treatment necessary to remove intron #1 DNA that would have interfered with mHTT-Tr transcript Ct values.
As seen in Figures 15A, 15B, and 15C, the mHTT-F1 transcript was specifically reduced at 1, 2, and 4 months, respectively, after treatment.
Figure 15D
shows that control-treated Q175 mice treated with a single unilateral ICV dose of control NC-a U1 AO at the highest concentration of 80 i.tg had no reduction in the mHTT-F1 transcript or the mHTT-Tr transcript.
Second, Q175 mice underwent a single unilateral ICV dose with the mHTT-Tr-a U1 AO at four different concentrations - 10, 20, 40, and 80 i.tg (mice n = 9 per dose) - giving 36 mice in total. A cohort of three mice from each concentration was euthanized after 1, 2, and 4 months where mice underwent perfusion with lx PBS
and then sacrificed. Hemibrains were collected and processed for analysis by RT-qPCR
and Northern blot. All Ul Adaptor treated mice were compared to untreated Q175 mice. Silencing of the mHTT-Tr transcript was assessed by RT-qPCR which were then compared to untreated mice set to 100%. RT-qPCR to detect mHTT-Tr transcript included Dnase treatment necessary to remove intron #1 DNA that would have interfered with mHTT-Tr transcript Ct values.
As seen in Figures 16A, 16B, and 16C, the mHTT-Tr transcript was specifically reduced at 1, 2, and 4 months, respectively, after treatment.
Silencing of the mHTT-Tr transcript by mHTT-Tr-a U1 AO was deemed specific because: 1) no significant changes in the mHTT-F1 transcript were observed and 2) the NC-a non-specific control U1A0 showed no silencing at the highest dose (80 g) at the 1, 2 and 4 month durations. Likewise, silencing of the mHTT-F1 transcript by mHTT-Fl-a U1A0 was deemed specific because: 1) no significant changes in the mHTT-Tr transcript were observed and 2) the NC-a non-specific control U1A0 showed no silencing at the highest dose (80 g) at the 1, 2 and 4 month durations.
Pharmacokinetics (PK) studies were also performed. A PK profile was achieved by 32P-Northern blot analysis over a four point dose response combined with a 3-point time-course duration of the same mice listed above. An aliquot of the same RNA used to perform RT-qPCR was used for Northern blotting. In brief, RNA
1 0 samples from Ul Adaptor-treated mice along with standards and a 32P
tracer were separated on an 8% denaturing urea-PAGE gel followed by transfer to a Northern blot membrane. The membrane was then probed with the cognate 32P-probe, washed and exposed to X-ray film. The cognate probes were a 32P-labelled oligonucleotide called 32P-anti-mHTT-FL-a that is antisense to the mHTT-Fl-a U1 AO or a 32P-labelled oligonucleotide called 32P-anti-mHTT-Tr-a that is antisense to the mHTT-Tr-a or a 32P-labelled oligonucleotide called 32P-anti-NC-a that is antisense to the NC-a U1 AO. After several exposures to X-ray film, the Northern blots were quantified by phosphoimager analysis on a TyphoonTm system. Results are provided in Figure 17.
The histopathology of the U1A0 was also studied. Briefly, YAC128 mice were ICV injected with saline (n = 3) or 50 [tg of hHTI-FL-2 Ul Adaptor Oligo in saline (n = 5). Two mice were used as untreated controls. The mice were all males and ranged in age from 3-5 months. Mice were treated for 7 days. Two hematoxylin and eosin (H&E) stained slides from brain, kidney and liver tissue from each mouse was examined for histopathology analysis. Microscopic examination of the above slides does not reveal specific histopathologic changes of toxicity related to ICV-50 g Ul Adaptor Oligo. Microscopic examination of the H&E slides did not reveal specific histopathologic changes of toxicity related to IC V-50 [tg Ul Adaptor Oligo.
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.
Several publications and patent documents are cited in the foregoing specification in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these citations is incorporated by reference herein.
hHTT-FL-2: mC+AmGmAmA+AmAmGmG+TmUmCmA+CmGmUmC+CmAmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 14), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
hHTT-TR-1: mA+GmGmGmU+TmAmCmC+GmCmCmA+TmCmCmC+CmGmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 15), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
hHTT-TR-2: mGmC+GmAmGmA+GmGmAmC+AmAmGmG+GmAmAmG+AmC
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 16), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
NC-a (ctrl): mAAmCmGmGmUmUmAmGmGmCmAmCmCmTmCmUmUmGmA
mGmCmCmAmGmGmUmAmAmGmUmAmU (SEQ ID NO: 17), wherein m = 2'-0-methyl;
mHTT-FL-A: mUmGmC+AmGmCmC+AmCmCmA+CmCmUmC+AmAmAmC+A
mGmCmC+AmGmG+TmA+AmGmU+AmU (SEQ ID NO: 18), wherein m = 2'-0-methyl and + = Locked Nucleic Acid; and mHTT-TR-A: mA+GmUmUmC+TmCmUmU+CmAmCmA+AmCmAmG+TmCmA
mGmCmC+AmGmG+TmA+AmGmU+AmU (SEQ ID NO: 19), wherein m = 2'-0-methyl and + = Locked Nucleic Acid;
siRNA:
hHTT-siRNA-1 (both strands presented; r = RNA):
5'-rGrGrA rUrArG rUrArG rArCrA rGrCrA rArUrA rArCrU rCrGG T-3' (SEQ ID NO: 20) 5'-rArCrC rGrArG rUrUrA rUrUrG rCrUrG rUrCrU rArCrU rArUrC rCrGrU-3' (SEQ ID NO: 21);
hHTT-siRNA-2 (both strands presented; r = RNA):
5'-rArGrA rArCrU rUrUrC rArGrC rUrArC rCrArA rGrArA rArGA C-3' (SEQ ID NO: 22) 5'-rGrUrC rUrUrU rCrUrU rGrGrU rArGrC rUrGrA rArArG rUrUrC rUrUrU-3' (SEQ ID NO: 23); and hHTT-siRNA-3 (both strands presented; r = RNA):
5'-rArCrA rGrCrU rCrCrA rGrCrC rArGrG rUrCrA rGrCrG rCrCG T-3' (SEQ ID NO: 24) 5'-rArCrGr GrCrG rCrTrG rArCrC rTrGrG rCrTrG rGrArG rCrTrG rTrTrG-3' (SEQ ID NO: 25).
Figure 3 provides a Western blot of Human DU145 cells transfected 48 hours (LipofectamineTM 2000) with various anti-hHTT-FL Ul AOs and siRNAs (see below).
Cells were lysed directly into laemmli buffer and then analyzed by Western blot after electrophoresis on a 6-20% gradient gel. The best anti-hHTT-FL Ul AOs (hHTT-FL-1 and hHTT-FL-2) were used here and show silencing activity at the protein level.
The anti-HTT-FL siRNA also showed silencing activity. Notably, using less U1A0 gave less silencing (compare lane 9 with lane 7).
YAC128 are mice containing the entire human HTT gene (300,000 bp) having 128 CAG repeats. To determine the effectiveness of the U1A0, either 1 or 20 of hHTT-FL-2 U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into YAC128 mice. After 48 hours, mice were sacrificed with perfusion. Total RNA
from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 4A, a 20 tg unilaterally-ICV-injected dose of the hHTT-FL-2 silences with a 62% reduction of the hHTT-F1 mRNA in YAC128 brain as compared to saline treated mice. The specificity of silencing is confirmed by the fact that neither the hHTT-Tr mRNA isoform (Fig. 4B) nor the Eif4a3 housekeeping gene underwent an observable change in expression.
Total RNA (4 tg /lane) from forebrains of YAC128 mice were analyzed by 32P Northern blot (8% PAGE) (Figure 5). Specifically, the blot was probed with a 33nt 32P-anti-hHTT-FL-2 oligonucleotide complementary to hHTT-FL-2 U1A0 in order to measure U1 AO levels. The lanes marked "Standards" are the uninjected U1A0 and their inclusion allows for a rigorous quantitation. As seen in Figure 5, the U1A0 in the brain tissue is neither degraded nor shortened. Shortening of the injected U1 AO, even by just a few nucleotides, would result in a noticeable change in migration relative to the standards.
An RNAScopeg analysis, a type of in situ hybridization (ISH) technology, was used to detect hHTT-FL transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to hHTT-FL mRNA. As seen in Figure 6, the hHTT-FL-2 U1 AO-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of hHTT-FL.
To further demonstrate the stability of hHTT-FL-2 U1 AO, 20 tg of hHTT-FL-2 U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into YAC128 mice. After 2, 4, or 7 days, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 7A, a 2011g unilaterally-ICV-injected dose of the hHTT-FL-2 U1 AO reduces hHTT-F1 mRNA in YAC128 brain constantly over time. Figure 7B
provides a Northern blot analysis probed with a 33nt32P-anti-hHTT-FL-2 oligonucleotide complementary to hHTT-FL-2 U1 AO in order to measure U1 AO
levels. As seen in Figure 7B, the U1 AO in the brain tissue is neither degraded nor shortened over time.
The ability to silence hHTT-Tr has also been demonstrated. 20 tg of hHTT-1 5 TR-1 U1A0, hHTT-TR-2 U1A0, or saline was unilaterally ICV injected into YAC128 mice. After 48 hours, mice were sacrificed with perfusion. Total RNA
from forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3).
As seen in Figure 8A, hHTT-TR-1 U1A0 did not effectively silence hHTT-TR whereas the hHTT-TR-2 U1A0 significantly silences hHTT-TR by about 79%. The effect was specific as no silencing was observed for the hHTT-FL mRNA in either the saline-treated or hHTT-TR-treated mice (Fig. 8B).
Anti-mouse HTT Ul AOs were also synthesized and shown to silence mHTT
in cultured cells. The best anti-mouse HTT Ul AOs were mHTT-TR-a (targeting mHTT-TR mRNA transcript) and mHTT-FL-a (targeting mHTT-FL mRNA
transcript). These Ul AOs were then tested in the Q175 mouse model. Q175 mice are a knock-in mice where, for heterozygotes, one of the HTT alleles has 175 CAG
repeat. To determine the effectiveness of the U1A0, saline, 20 of mHTT-TR-A
U1 AO, or 40 tg of non-specific control adaptor (NC-A) U1 AO was unilaterally ICV
injected into Q175 mice. The NC-A U1A0 is a non-specific control U1A0 designed to not silence any mouse gene. After 48 hours, mice were sacrificed with perfusion.
Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor (Eif4a3). As seen in Figure 9A, a 20 tg unilaterally-ICV-injected dose of the mHTT-TR-A U1A0 silences with a 75% reduction of the mHTT-TR mRNA in Q175 brain as compared to control treated mice. The specificity of silencing is confirmed by the fact that neither the mHTT-FL mRNA isoform (Fig. 9B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
An RNAScopeg analysis was also performed to detect mHTT-TR transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to mHTT-TR mRNA. As seen in Figure 10, the mHTT-TR-A U1 AO-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of mHTT-TR.
To further demonstrate the stability of mHTT-TR-A U1 AO, 20 tg of mHTT-1 5 TR-A U1 AO or saline was unilaterally intracerebroventricular (ICV) injected into Q175 mice. After 21 days, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR
and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3). As seen in Figure 11A, a 20 tg unilaterally-ICV-injected dose of the mHTT-TR-A U1 AO
reduces mHTT-TR mRNA in Q175 mouse brain even after 21 days. The specificity of silencing is confirmed by the fact that neither the mHTT-FL mRNA isoform (Fig.
11B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
To determine the effectiveness of the mHTT-FL U1A0, saline, 40 tg of mHTT-FL-A U1 AO, or 40 tg of non-specific control adaptor (NC-A) U1 AO was unilaterally ICV injected into Q175 mice. The NC-A U1A0 is a non-specific control U1A0 designed to not silence any mouse gene. After 48 hours, mice were sacrificed with perfusion. Total RNA from left forebrains was extracted by a Trizol-based method and was analyzed by RT-qPCR and normalized to eukaryotic translation initiation factor 4A3 (Eif4a3). As seen in Figure 12A, a 40 unilaterally-ICV-injected dose of the mHTT-FL-A U1A0 silences with a 69% reduction of the mHTT-FL mRNA in Q175 brain as compared to control treated mice. The specificity of silencing is confirmed by the fact that neither the mHTT-TR mRNA isoform (Fig.
12B) nor the Eif4a3 housekeeping gene underwent a significant change in expression.
An RNAScopeg analysis was also performed to detect mHTT-FL transcripts at single cell resolution. Briefly, the RNAScopeg method involves fixing the hemibrain in 4% paraformaldehyde for 48 hours, transferring to PBS, and processing through tissue processor for paraffin embedding. The formalin-fixed paraffin-embedded (FFPE) brains were cut at 5 microns thick through the sagittal plane and striatal sections followed by in situ hybridization using an RNAScopeg probe specific to mHTT-FL mRNA. As seen in Figure 13, the mHTT-FL-A U1A0-treated mice (right) have fewer dots and a reduced intensity as compared to saline treated mice (left), thereby demonstrating silencing of mHTT-FL.
Biodistribution studies for hHTT-FL-2 U1A0 were also performed. Briefly, to assess biodistribution in brain regions at the single cell level, a series of experiments was performed with a Cy3-fluorescently labelled hHTT-FL-2 U1A0 (Cy3-hHTT-FL-2 U1A0). 5 ig of Cy3-hHTT-FL-2 U1A0 was unilaterally ICV-inj ected into 6-8 month old YAC128 mice. At 1, 7, and 28 days post-injection, mice were sacrificed with perfusion (with saline) to remove blood and extracellular U1A0.
Brain samples were subsequently studied by confocal microscopy. Notably, higher doses of Cy3-hHTT-FL-2 U1 AO were not used because the Cy3 fluorescent group itself proved toxic. Indeed, the injection of 1.5 and 4 of free Cy3, which is the stoichiometric equivalent of 30 tg and 80 tg Cy3-hHTT-FL-2 U1A0, respectively, was determined to be highly toxic to YAC128 mice. The use of 5 tg of Cy3-hHTT-FL-2 U1A0 resulted in no overt toxic effects in YAC128 mice.
The biodistribution assays showed that after Cy3-hHTT-FL-2 U1 AO was ICV-injected into the left ventricle, Cy3-hHTT-FL-2 U1A0 rapidly (within 1 day) and significantly distributed across both left and right hemibrains, resulting in symmetric distribution of Cy3-hHTT-FL-2 U1 AO in both the left and right side of the brain by days 7 and 28. These results show that Cy3-hHTT-FL-2 U1A0 quickly migrates from the left-ventricle injection site into other brain regions (e.g., striatum, cortex, hippocampus, cerebellum), including right hemibrain regions that are farthest from the injection site. Cy3-hHTT-FL-2 U1 AO also had widespread uptake by most neurons (e.g., cortical neurons) and cell types. Additionally, Cy3-hHTT-FL-2 was clearly visible in the nucleus and perinucleus. Lastly, fluorescent intensity was only slightly diminished at the 28 day time point as compared to the 1 and 7 day time points, thereby demonstrating the stability of Cy3-hHTT-FL-2 U1 AO over time.
Further experiments were performed to demonstrate 50% to 80% sustained reduction of the mHTT-F1 transcript from one to four months. In parallel experiments, conditions were identified that achieved 50% to 80% sustained reduction of the mHTT-Tr transcript from one to four months.
First, Q175 mice underwent a single unilateral ICV dose with the mHTT-FL-a U1A0 at four different concentrations - 10, 20, 40, and 80 i.tg (mice n = 9 per dose) -giving 36 mice in total. A cohort of three mice from each concentration was euthanized after 1, 2, and 4 months where mice underwent perfusion with lx PBS
and then sacrificed. Hemibrains were collected and processed for analysis by RT-qPCR
and Northern blot. All Ul Adaptor treated mice were compared to untreated Q175 mice. Silencing of the mHTT-F1 transcript was assessed by RT-qPCR which were then compared to untreated mice set to 100%. RT-qPCR to detect mHTT-Tr transcript included Dnase treatment necessary to remove intron #1 DNA that would have interfered with mHTT-Tr transcript Ct values.
As seen in Figures 15A, 15B, and 15C, the mHTT-F1 transcript was specifically reduced at 1, 2, and 4 months, respectively, after treatment.
Figure 15D
shows that control-treated Q175 mice treated with a single unilateral ICV dose of control NC-a U1 AO at the highest concentration of 80 i.tg had no reduction in the mHTT-F1 transcript or the mHTT-Tr transcript.
Second, Q175 mice underwent a single unilateral ICV dose with the mHTT-Tr-a U1 AO at four different concentrations - 10, 20, 40, and 80 i.tg (mice n = 9 per dose) - giving 36 mice in total. A cohort of three mice from each concentration was euthanized after 1, 2, and 4 months where mice underwent perfusion with lx PBS
and then sacrificed. Hemibrains were collected and processed for analysis by RT-qPCR
and Northern blot. All Ul Adaptor treated mice were compared to untreated Q175 mice. Silencing of the mHTT-Tr transcript was assessed by RT-qPCR which were then compared to untreated mice set to 100%. RT-qPCR to detect mHTT-Tr transcript included Dnase treatment necessary to remove intron #1 DNA that would have interfered with mHTT-Tr transcript Ct values.
As seen in Figures 16A, 16B, and 16C, the mHTT-Tr transcript was specifically reduced at 1, 2, and 4 months, respectively, after treatment.
Silencing of the mHTT-Tr transcript by mHTT-Tr-a U1 AO was deemed specific because: 1) no significant changes in the mHTT-F1 transcript were observed and 2) the NC-a non-specific control U1A0 showed no silencing at the highest dose (80 g) at the 1, 2 and 4 month durations. Likewise, silencing of the mHTT-F1 transcript by mHTT-Fl-a U1A0 was deemed specific because: 1) no significant changes in the mHTT-Tr transcript were observed and 2) the NC-a non-specific control U1A0 showed no silencing at the highest dose (80 g) at the 1, 2 and 4 month durations.
Pharmacokinetics (PK) studies were also performed. A PK profile was achieved by 32P-Northern blot analysis over a four point dose response combined with a 3-point time-course duration of the same mice listed above. An aliquot of the same RNA used to perform RT-qPCR was used for Northern blotting. In brief, RNA
1 0 samples from Ul Adaptor-treated mice along with standards and a 32P
tracer were separated on an 8% denaturing urea-PAGE gel followed by transfer to a Northern blot membrane. The membrane was then probed with the cognate 32P-probe, washed and exposed to X-ray film. The cognate probes were a 32P-labelled oligonucleotide called 32P-anti-mHTT-FL-a that is antisense to the mHTT-Fl-a U1 AO or a 32P-labelled oligonucleotide called 32P-anti-mHTT-Tr-a that is antisense to the mHTT-Tr-a or a 32P-labelled oligonucleotide called 32P-anti-NC-a that is antisense to the NC-a U1 AO. After several exposures to X-ray film, the Northern blots were quantified by phosphoimager analysis on a TyphoonTm system. Results are provided in Figure 17.
The histopathology of the U1A0 was also studied. Briefly, YAC128 mice were ICV injected with saline (n = 3) or 50 [tg of hHTI-FL-2 Ul Adaptor Oligo in saline (n = 5). Two mice were used as untreated controls. The mice were all males and ranged in age from 3-5 months. Mice were treated for 7 days. Two hematoxylin and eosin (H&E) stained slides from brain, kidney and liver tissue from each mouse was examined for histopathology analysis. Microscopic examination of the above slides does not reveal specific histopathologic changes of toxicity related to ICV-50 g Ul Adaptor Oligo. Microscopic examination of the H&E slides did not reveal specific histopathologic changes of toxicity related to IC V-50 [tg Ul Adaptor Oligo.
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.
Several publications and patent documents are cited in the foregoing specification in order to more fully describe the state of the art to which this invention pertains. The disclosure of each of these citations is incorporated by reference herein.
Claims (31)
1. A Ul adaptor oligonucleotide for inhibiting the expression of the huntingtin gene, wherein said Ul adaptor oligonucleotide is a nucleic acid molecule comprising an annealing domain operably linked to at least one effector domain, wherein said annealing domain hybridizes to the pre-mRNA of said huntingtin gene, and wherein said effector domain hybridizes to the Ul snRNA of Ul snRNP.
2. The Ul adaptor oligonucleotide of claim 1, wherein said annealing domain is about 10 to about 30 nucleotides in length.
3. The Ul adaptor oligonucleotide of claim 1, wherein said effector domain is about 8 to about 20 nucleotides in length.
1 5 4. The Ul adaptor oligonucleotide of claim 1, wherein said effector domain and annealing domain are linked by a bond or a linker domain of about 1 to about nucleotides.
5. The Ul adaptor oligonucleotide of claim 1, wherein said effector domain comprises 2 0 the sequence 5'-CAGGUAAGUA-3' (SEQ ID NO: 1), 5'-CAGGUAAGUAU-3' (SEQ ID NO: 4), or 5'-GCCAGGUAAGUAU-3' (SEQ ID NO: 5).
6. The Ul adaptor oligonucleotide of claim 1, further comprising at least one targeting moiety and/or cell penetrating moiety, wherein said targeting moiety and/or cell 2 5 penetrating moiety is operably linked to said Ul adaptor oligonucleotide.
7. The Ul adaptor oligonucleotide of claim 1, wherein said Ul adaptor oligonucleotide comprises at least one nucleotide analog.
3 0 8. The Ul adaptor oligonucleotide of claim 1, wherein said Ul adaptor oligonucleotide comprises 2'-0-methyl nucleotides, 2'-0-methyloxyethoxy nucleotides, 2'-halo (e.g., 2'-fluoro), and/or locked nucleic acids.
9. The Ul adaptor oligonucleotide of claim 1, wherein Ul adaptor oligonucleotide comprises phosphorothioates.
10. The Ul adaptor oligonucleotide of claim 1, wherein said annealing domain hybridizes with a target sequence in the 3' terminal exon of the huntingtin gene.
11. The Ul adaptor oligonucleotide of claim 1, wherein the effector domain is operably linked to the 3' end of the annealing domain, the 5' end of the annealing domain, or both the 5' and 3' end of the annealing domain.
12. The Ul adaptor oligonucleotide of claim 1, wherein said annealing domain comprises a stretch of at least seven deoxyribonucleotides.
13. The Ul adaptor oligonucleotide of claim 1, wherein said Ul snRNA is a Ul 1 5 variant snRNA.
14. The Ul adaptor oligonucleotide of claim 6, wherein said Ul adaptor oligonucleotide and said targeting moiety and/or cell penetrating moiety are conjugated via a linker.
15. The Ul adaptor oligonucleotide of claim 14, wherein said linker is cleavable.
16. The Ul adaptor oligonucleotide of claim 6, wherein said targeting moiety and/or cell penetrating moiety is operably linked to the 3' end, the 5' end, or both the 5' and 2 5 3' end of the Ul adaptor oligonucleotide.
17. The Ul adaptor oligonucleotide of claim 16, wherein said targeting moiety and/or cell penetrating moiety is operably linked to the 5' end of the Ul adaptor oligonucleotide.
18. The Ul adaptor oligonucleotide of claim 1, wherein said Ul adaptor oligonucleotide is operably linked to a first targeting moiety at the 3' end and a second targeting moiety at the 5' end.
19. The Ul adaptor oligonucleotide of claim 6, wherein said targeting moiety is an antibody or fragment thereof.
20. The Ul adaptor oligonucleotide of claim 1, wherein the Ul adaptor oligonucleotide inhibits the expression of the full-length and/or truncated huntingtin mRNA.
21. The Ul adaptor oligonucleotide of claim 1, wherein the Ul adaptor oligonucleotide comprises a sequence selected from the group consisting of SEQ
ID
NO: 8, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 9, SEQ ID NO: 39, SEQ ID
NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID
NO: 15, and SEQ ID NO: 16.
ID
NO: 8, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 9, SEQ ID NO: 39, SEQ ID
NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID
NO: 15, and SEQ ID NO: 16.
22. The Ul adaptor oligonucleotide of claim 1, wherein the Ul adaptor 1 5 oligonucleotide comprises a sequence selected from the group consisting of SEQ ID
NO: 8, SEQ ID NO: 9, and SEQ ID NO: 15.
NO: 8, SEQ ID NO: 9, and SEQ ID NO: 15.
23. The Ul adaptor oligonucleotide of claim 1, wherein the annealing domain hybridizes with a sequence selected from the group consisting of SEQ ID NOs:
26-36.
26-36.
24. The Ul adaptor oligonucleotide of claim 1, wherein the annealing domain hybridizes with a sequence selected from the group consisting of SEQ ID NO:
26, SEQ ID NO: 29, and SEQ ID NO: 35.
26, SEQ ID NO: 29, and SEQ ID NO: 35.
2 5 25. A composition comprising at least one Ul adaptor oligonucleotide of any one of claims 1-24 and at least one pharmaceutically acceptable carrier.
26. The composition of claim 25, wherein said composition further comprises at least one siRNA or antisense oligonucleotide directed against said huntingtin gene.
27. A method of inhibiting the expression of the huntingtin gene comprising delivering to a cell at least one Ul adaptor oligonucleotide of any one of claims 1-24.
28. The method of claim 27, wherein at least two of said Ul adaptor oligonucleotides are delivered and wherein the annealing domains of said Ul adaptor oligonucleotides hybridize with different target sequences in said huntingtin gene.
29. A method of treating Huntington's disease in a subject in need thereof, said method comprising administering at least one Ul adaptor oligonucleotide of any one of claims 1-24 to said subject.
30. The method of claim 29, wherein at least two of said Ul adaptor oligonucleotides 1 0 are administered and wherein the annealing domains of said Ul adaptor oligonucleotides hybridize with different target sequences in said huntingtin gene.
31. The method of claim 29, further comprising the administration of at least one siRNA or antisense oligonucleotide directed against said huntingtin gene.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962815647P | 2019-03-08 | 2019-03-08 | |
US62/815,647 | 2019-03-08 | ||
PCT/US2020/021652 WO2020185651A2 (en) | 2019-03-08 | 2020-03-09 | Compositions and methods for treating huntington's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3132388A1 true CA3132388A1 (en) | 2020-09-17 |
Family
ID=72428020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3132388A Pending CA3132388A1 (en) | 2019-03-08 | 2020-03-09 | Compositions and methods for treating huntington's disease |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3935167A2 (en) |
JP (1) | JP2022524383A (en) |
KR (1) | KR20220002882A (en) |
CN (1) | CN113924364A (en) |
AU (1) | AU2020238872A1 (en) |
BR (1) | BR112021017635A2 (en) |
CA (1) | CA3132388A1 (en) |
IL (1) | IL286083A (en) |
SG (1) | SG11202109180RA (en) |
WO (1) | WO2020185651A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024035952A1 (en) * | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900016B1 (en) * | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
US9441221B2 (en) * | 2007-03-30 | 2016-09-13 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
MX2010008326A (en) * | 2008-01-29 | 2010-08-18 | Proyecto Biomedicina Cima Sl | Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner. |
AU2015252117A1 (en) * | 2008-04-11 | 2015-11-26 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US9809817B2 (en) * | 2015-04-03 | 2017-11-07 | University Of Massachusetts | Oligonucleotide compounds for targeting huntingtin mRNA |
-
2020
- 2020-03-09 CN CN202080019190.5A patent/CN113924364A/en active Pending
- 2020-03-09 CA CA3132388A patent/CA3132388A1/en active Pending
- 2020-03-09 BR BR112021017635A patent/BR112021017635A2/en not_active Application Discontinuation
- 2020-03-09 JP JP2021553317A patent/JP2022524383A/en active Pending
- 2020-03-09 EP EP20770560.9A patent/EP3935167A2/en not_active Withdrawn
- 2020-03-09 WO PCT/US2020/021652 patent/WO2020185651A2/en unknown
- 2020-03-09 SG SG11202109180RA patent/SG11202109180RA/en unknown
- 2020-03-09 KR KR1020217032259A patent/KR20220002882A/en unknown
- 2020-03-09 AU AU2020238872A patent/AU2020238872A1/en not_active Abandoned
-
2021
- 2021-09-02 IL IL286083A patent/IL286083A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021017635A2 (en) | 2021-11-09 |
IL286083A (en) | 2021-10-31 |
SG11202109180RA (en) | 2021-09-29 |
EP3935167A2 (en) | 2022-01-12 |
AU2020238872A1 (en) | 2021-09-16 |
KR20220002882A (en) | 2022-01-07 |
JP2022524383A (en) | 2022-05-02 |
WO2020185651A3 (en) | 2020-10-29 |
WO2020185651A2 (en) | 2020-09-17 |
CN113924364A (en) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7420679B2 (en) | Antisense oligomers for the treatment of conditions and diseases | |
Jafar-Nejad et al. | The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration | |
US20220170023A1 (en) | Modulation of prekallikrein (pkk) expression | |
CN105637090B (en) | Compositions for modulating expression of C9ORF72 | |
JP2022526419A (en) | Compositions and Methods for Inhibiting Gene Expression in the Central Nervous System | |
KR20220104677A (en) | Compositions and methods for modulating splicing and protein expression | |
CA3142526A1 (en) | Oligonucleotides and methods of use for treating neurological diseases | |
JP2018531046A (en) | Nucleic acid based TIA-1 inhibitors | |
JP2018531046A6 (en) | Nucleic acid based TIA-1 inhibitors | |
JP2016530887A (en) | Antisense oligomers and methods for treating SMN-related pathologies | |
JP2023548658A (en) | Selective delivery of oligonucleotides to glial cells | |
CA3132388A1 (en) | Compositions and methods for treating huntington's disease | |
JP2023519518A (en) | Antisense oligomers for treatment of disease | |
US20220372488A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
JP6478416B2 (en) | Pharmaceutical composition for the treatment of chronic kidney disease | |
CA3185488A1 (en) | Treatment of neurological diseases using modulators of gene transcripts | |
JP2021534799A (en) | How to Target Kits Using Splice Switching Oligonucleotides to Induce Mast Cell Apoptosis | |
CN114127288A (en) | Modulators and modulation of advanced glycosylation end product receptor RNA | |
JP6885596B2 (en) | Treatment of multiple sclerosis | |
US20170362590A1 (en) | Pharmaceutical compositions comprising microrna | |
US9840705B2 (en) | Materials and methods for treatment of pulmonary arterial hypertension | |
US20230416743A1 (en) | Compositions and methods for inhibiting snca expression | |
WO2014095916A1 (en) | Ninjurin-1 as therapeutic target for brain tumor | |
WO2023247738A1 (en) | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression |